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1. Introduction 
 
1.1 Multiple sclerosis: autoimmunity versus oligodendrogliopathy 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
characterized by myelin loss, oligodendrocyte death, inflammation and various degrees of 
axonal damage [1]. Oligodendrocytes as the principal target in MS pathology maintain the 
myelin sheath of up to 40 neighbouring axons. In consequence, oligodendrocyte death and 
destruction of the myelin sheath result in disturbances of saltatory conduction, axon 
degeneration and neuronal loss and thus lead to the variety of neurological symptoms 
observed in MS patients [2]. MS occurs usually in young adults between 20 and 40 years of 
age with a particular higher prevalence in women. With 2 to 2.5 million people affected 
worldwide it is the most-common chronic inflammatory disease of the CNS [3-4]. The first 
clinico-pathological description was given in 1868 by the French neurologist Jean-Martin 
Charcot (1825-1893) and almost 150 years later the cause of MS is still unknown [3]. 
For long MS was exclusively discussed as an autoimmune disorder with autoreactive T-cells 
directed against myelin components as the disease trigger [5]. This view was partially build 
on and supported by research obtained in one of the most common MS animal models: 
experimental autoimmune encephalomyelitis (EAE) [6]. EAE is a model that leads to T-cell 
driven inflammatory demyelination in the spinal cord due to immunization with myelin 
proteins or spinal cord homogenates [7-9]. Although MS and EAE have some features in 
common, like involvement of the adaptive immune response in CNS inflammation or clinical 
disease course, several differences exist between the model and the disease, which cannot be 
explained with an exclusive autoimmune view of the disease [10-13]. In the past ten years 
researchers have investigated biopsies and autopsies of MS patients and made a significant 
discovery: in CNS tissue of MS patients pathological changes occur in the absence of T-cell 
driven inflammation and demyelination [14-20]. Among others, they found activation of 
microglial cells [14-15, 21] as well as increased expression of anti-apoptotic genes in 
oligodendrocytes and apoptotic oligodendrocytes [19, 22]. Based on this observations some 
researchers claimed that the different lesion patterns described in MS [23] should not be 
considered as different types of the disease, but rather as different time points in disease 
development [11-12]. In this view, early pathological changes (microglia activation and 
oligodendrogliopathy) with no or very little adaptive immune response precede the formation 
of an active demyelinating lesion with strong adaptive immune response, finally followed by 
the development of a chronic lesion with decreasing inflammation [1, 20]. The responsible 
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trigger causing this early changes is completely unknown, but different genetical and 
environmental risk factors have long been discussed in the context of MS, for example 
viruses, chemicals or lack of vitamin D, but none was proven so far [24-29]. Suggesting that 
oligodendrogliopathy and activation of microglial cells as the major cells of CNS innate 
immune response [30-32] are the first steps in MS lesion development, leads to the question 
what factors are responsible for microglia activation in the absence of demyelination and thus 
myelin debris? For instance, it has been shown that the small heat shock protein α-B-
Crystallin is expressed in oligodendrocytes in the normal appearing white matter (NAWM) of 
MS patients and is able to activate microglial cells [33]. It is likely that further factors, such as 
cytokines or chemokines, are also involved in the observed microglia activation. The initial 
activation of microglial cells might alter the integrity of the blood brain barrier leading to 
activation and recruitment of peripheral immune cells as found in active demyelinating MS 
lesions. Since the EAE model is primarily an adaptive immune driven model, other animal 
models are necessary to study details of this scenario, where the adaptive immune response 
plays no or only a minor role. A well described model to study demyelination in vivo, which 
is not of an autoimmune origin is the cuprizone model. In the past years, the cuprizone model 
was extensively characterized with respect to de- and remyelination properties and the 
complex cell-cell interactions during these processes [34-39]. Feeding of cuprizone, 
chemically a copper chelator, induces demyelination of many CNS white and grey matter 
regions, notably the corpus callosum (CC) [34]. In this model, oligodendrogliopathy results in 
significant oligodendrocyte apoptosis with concomitant microglial activation, astrocytosis, 
and finally active demyelination [35-36, 40-41]. The underlying biochemical and cellular 
mechanisms of these alterations are, however, still poorly understood. Extensive 
investigations of these mechanisms will help to understand the molecular changes during 
oligodendrogliopathy and microglia activation not only in the cuprizone model, but also in 
MS. This has further implications for the understanding of disease mechanisms and for the 
development of future treatment strategies. 
 
1.2 Oligodendrocytes in multiple sclerosis 
In the central nervous system functionality of neurons depends on the integrity of the myelin 
sheath. The myelin sheath is build up by oligodendrocytes that tightly enwrap neuronal axons 
with concentrical loops of their plasma membrane. Disturbance of the myelin sheath leads to 
severe failure in action potential conduction and thus problems on various levels such as 
cognitive, sensory- and motorfunctions. Myelinating oligodendrocytes originate from 
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oligodendrocyte progenitor cells (OPCs) which are generated in the ventral epithelium of the 
neural tube in early embryonic life [42-43] and in the dorsal spinal cord, hindbrain and 
telencephalon in late embryonic development and early post-natal life [44-47]. During 
development OPCs migrate into the developing white matter [48-50], exit the cell cycle, 
undergo differentiation into mature oligodendrocytes and begin to express a subset of myelin-
associated proteins [51-52]. When an oligodendrocyte gets in close contact to an un-
myelinated axon it starts to enwrap it with flat membrane sheets. Myelin components are 
synthesized and transported to the appropriate region within the sheath. Finally, when the 
axon is wrapped, the myelin membrane is compacted such that myelin leaflets are practically 
fused and almost devoid of cytoplasm [53-56]. In the CNS, one single oligodendrocyte can 
produce up to 40 myelin segments on different axons. This means, myelinating 
oligodendrocytes produce as much as 5-50 × 10³ µm² of membrane per day [57]. It is clear 
that maintaining this membrane needs a continual high turnover of myelin and is correlated 
with high levels of myelin gene expression long after the completion of the myelination 
process [58-59]. The maintenance of this enormous membrane makes oligodendrocytes 
particularly vulnerable to pathologic changes as they are confronted with several metabolic 
challenges. First, oligodendrocytes have an extremely high metabolic rate and consume large 
amounts of ATP and oxygen, which leads to the production of hydrogen peroxide and 
reactive oxygen species as by-products [60]. Second, many of the myelin synthetic enzymes 
require iron as a co-factor [61] which can under unfavourable conditions evoke free radical 
formation and lipid peroxidation [62-63]. The problem of oxidative stress is even more severe 
as oligodendrocytes exhibit only low levels of the anti-oxidative enzyme glutathione [64]. 
Third, the endoplasmatic reticulum of oligodendrocytes works on the upper limit of its 
capacity due to high myelin protein synthesis. Already small changes in the amount of a 
single protein can easily result in missfolding and accumulation of other proteins in this 
organelle, leading to endoplasmatic reticulum stress and, if not eliminated by corresponding 
rescue pathways, possibly apoptosis [65-67]. Taken together these unique metabolic features 
of oligodendrocytes makes them a vulnerable cell population under pathological changes in 
the CNS. 
In MS the destruction of myelin and oligodendrocyte apoptosis leads to the typical 
demyelinating lesions. Whether lesions develop due to inflammation in an autoimmune 
manner or due to high vulnerability of oligodendrocytes to a still unknown trigger with 
inflammation as a secondary phenomenon, is topic of a controversial debate (see 1.1). 
Nevertheless, recent findings suggest that oligodendrocyte apoptosis and accompanying 
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microglia activation precede the infiltration of the brain parenchyma with peripheral immune 
cells like macrophages and T-cells and the formation of demyelinating plaques [19, 68-69]. 
Therefore, the view that oligodendrocytes are only ‘passive victims’ during MS lesion 
development and progression should be reconsidered. For example, experimental studies 
showed that the absence of oligodendrocyte protective factors increases oligodendrocyte 
susceptibility to injury and augments the inflammatory reaction [70]. In addition, mice 
lacking pro-apoptotic genes, or over-expressing anti-apoptotic molecules, exclusively in 
oligodendrocytes, display resistance to EAE [71-72]. This resistance is paralleled by reduced 
numbers of infiltrating T-cells and macrophages/microglia in the EAE lesions [71]. These 
examples promote the view that myelinating oligodendrocytes can control neuroinflammatory 
and demyelinating processes in the brain. Whether this control is a passive effect due to less 
oligodendrocyte apoptosis or if it is actively controlled by the secretion of inflammatory 
factors was not systematically investigated in these studies. In this context the cuprizone 
model is of particular interest to study the microenvironment during oligodendrocyte damage, 
as it displays a primary oligodendrogliopathy with significant oligodendrocyte apoptosis and 
concomitant microglia activation [35-36, 40-41, 73]. Thus, the cuprizone model provides the 
pathological conditions needed to investigate the presence of oligodendrocyte-derived 
inflammatory factors and possible effects on microglia activation. 
Another important aspect of oligodendrocyte biology in the context of MS is their capacity to 
remyelinate axons after demyelination [74]. During remyelination OPCs, which are located 
throughout the adult grey and white matter [75-76], proliferate and migrate into the 
demyelinated lesion site, differentiate to mature oligodendrocytes and start to enwrap 
demyelinated axons. This important repair mechanism is jointly responsible to retrieve axonal 
function and restore clinical disability in MS patients to a certain extent. For the majority of 
MS patients this repair mechanism ultimately fails leading to persistent demyelination, axonal 
loss and progressive clinical decline. Why remyelination failure occurs in MS is poorly 
understood [77], but it seems that the differentiation of OPCs is inhibited, preventing their 
maturation and thus myelination [78]. The process of remyelination involves different 
signalling pathways which influence proliferation and differentiation of OPCs. For example 
the growth factors platelet derived growth factor α (PDGFα) and basic fibroblast growth 
factor (FGF-2) are involved in OPC proliferation, suppress differentiation and myelin protein 
production [79-84] and have been described to be expressed after demyelination [85]. Among 
others, both factors might be involved in remyelination failure in MS. A better understanding 
what factors drive OPC proliferation and possibly inhibit OPC differentiation, would offer 
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novel clues for therapeutic intervention to promote OPC differentiation and thus 
remyelination. 
 
1.3 Chemokines in multiple sclerosis 
Chemokines represent a group of chemotactic proteins, playing important roles during 
leucocyte attraction and activation under inflammatory conditions [86-89]. Chemokines are 
relatively small proteins with a molecular weight from 8 to 14 kDa. They can be subdivided 
into four groups, depending on the number and spacing of conserved cysteine residues in their 
amino termini (compare Fig. 1) [90-91]. Today, approximately 50 chemokines [92] and 20 
corresponding receptors [93] have been described in human, with orthologs in other 
mammalian species [89, 94]. 
 
Figure 1 Structure of chemokine classes 
Chemokines consist of four subfamilies which are distinguished by the number and spacing of conserved 
cysteine residues in their amino termini. The largest chemokine classes are the CC and CXC chemokines, 
whereas the C and CX3C chemokine families consist only of two or one member, respectively. 
 
Chemokines signal through a group of seven-transmembrane G-protein coupled receptors 
(GPCRs), which are expressed on various cells including immune cells as well as astrocytes, 
oligodendrocytes, microglia and neurons [95]. Due to the diversity of down-stream GPCR 
signalling, chemokines may control a broad spectrum of cellular functions, among cell 
migration [96-97]. Furthermore, most chemokines display affinity for more than one receptor 
making their action more complex compared to other cytokines. Beside the classical GPCRs 
atypical receptor-like molecules exist, which do not show classical chemokine receptor 
function but significantly regulate the complex chemokine network, making chemokine 
functions even more versatile [98-100]. In addition, chemokine function can be negatively 
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regulated by chemokine receptor desensitization and internalization upon ligand binding [101-
102]. 
Beside their role in immune response chemokines execute a variety of functions in the CNS. 
They are involved in migration and development of neural stem cells [103-104], regulate the 
growth of axons during neuronal development [105-106], are discussed to influence electrical 
activity in neurons [107-108] and have been shown to co-ordinate the communication 
between neurons and microglial cells under distinct neuropathological conditions [109]. 
Furthermore, chemokines induce proliferation [110-111] and migration of astrocytes in vitro 
[112-116] indicating a role during the formation of astrogliosis. The induction of chemokines 
and their receptors in various pathologies of the CNS, like Alzheimer’s disease, Behçet’s 
disease, HIV-1-associated dementia, human T-cell leukemia virus-1-associated myelopathy or 
brain injury [117-118] argue for an important role of the chemokine system in 
neuropathology. Regarding MS, a variety of chemokines and chemokine receptors is induced 
in this demyelinating disease and has been demonstrated in both acute and chronic MS lesions 
(reviewed in [119]). This included among others monocyte chemotactic protein-1 (MCP1 or 
CCL2), macrophage inflammatory protein-1α (MIP1α or CCL3) and interferon-inducible 
protein-10 (IP10 or CXCL10) [119], all described to be involved in immune cell activation. 
Through construction of transgenic and knockout mice, much progress has been made in our 
understanding of chemokine action in vivo. Several research groups have used EAE to probe 
CNS chemokine expression and function. CCL2-deficient mice were markedly resistant to 
EAE, and showed a significant reduction in macrophage recruitment into the CNS [120]. 
Karpus and colleagues showed that anti-CCL3 antibodies suppress initial attacks of adoptive-
transfer EAE, while anti-CCL2 antibodies inhibit subsequent relapses, indicating that specific 
chemokines execute no redundant functions in these disease models [121-123]. Furthermore, 
CXCL10 levels have been correlated with the development of EAE, and the recruitment of T-
cells expressing the CXCL10 receptor CXCR3. In mice treated with anti-CXCL10 antibodies 
a lower accumulation of inflammatory mononuclear cells and decreased incidence of EAE 
were observed [124]. These results could not be confirmed in a more recent study using anti-
CXCL10 antibodies and CXCL10 deficient mice were even more susceptible to EAE [125-
127], highlighting the complex role of chemokines under pathological conditions. Moreover, 
one should consider that EAE does not fully reflect the situation in MS, but it is highly 
probable that chemokines and their receptors are involved in MS pathogenesis [128]. 
Taking together, the role of chemokines in MS has been mainly discussed in terms of 
inflammatory recruitment of leukocytes across the blood brain barrier during lesion 
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progression [129-130]. However, the effects of these chemokines in the initial phase of lesion 
development on brain parenchymal cells, in particular microglia and astrocytes, remain to be 
elucidated. 
 
1.4 Microglia in multiple sclerosis 
Microglial cells are the brain resident immune cells with capacity of antigen presentation and 
phagocytosis [30-32]. During embryonic development and early postnatal life it is believed 
that monocytes invade the brain parenchyma and transform into microglial cells with similar 
properties as macrophages in other tissues [131].During life microglia might be replaced 
either by cell division [132] or by recruitment of blood-borne monocytes, which then 
transform into new microglia [133].Under physiological conditions the so called “ramified” 
microglia are highly dynamic cells, which send out or withdraw their numerous processes to 
control and observe the brain parenchyma [134-135]. Upon an insult targeted movement of 
microglia processes was observed and the number of responding cells was proportional to the 
severity of the insult [134, 136].Under pathological conditions such as MS the activated 
microglia undergoes morphological changes from a ramified cell with long and thin processes 
to a cell with fewer and thicker processes [137]. Furthermore microglial cells migrate through 
the tissue towards the site of injury for instance to clear cellular debris (i.e. myelin). In 
addition the cells also release cytokines, radicals as well as neurotrophic factors [31-32, 138-
139] thus are able to influence the injury site in various ways. Beside the activation of CNS-
intrinsic microglia, blood-borne monocytes enter the CNS perivascular spaces and 
parenchyma upon an injury and transform into a macrophage phenotype. Since there are no 
specific immunohistochemical markers it is difficult to discriminate both cell types, therefore 
the cells are often referred to as “macrophages/microglia”. 
The accumulation of macrophages/microglia in the injured CNS has been examined in various 
diseases of the CNS e.g. Alzheimer´s disease, MS and spinal cord injury [140-141]. In EAE 
microglia activation coincided with an increase of pro-inflammatory monocytes in the blood 
followed by their entry into the CNS just prior to the development of clinical signs [142]. The 
entry of monocytes may guide the infiltration of T-cells into the CNS parenchyma as 
supported by the findings of Tran et al. who chemically depleted macrophages in EAE 
leading to reduced infiltration of lymphocytes in the spinal cord parenchyma as they were 
trapped in the perivascular space unable to cross the glia limitans formed by astrocytes [143]. 
These findings indicate that macrophages/microglia play an important role during disease 
development in this model. Furthermore, in EAE and MS disease severity positively 
13 
 
correlates with the presence of activated macrophages in the CNS [144]. In active 
demyelinating MS plaques the number of macrophages/microglia exceeds the number of 
lymphocytes by as much as 10-20 times [23, 145-146] and is still remarkable at the borders of 
chronic active plaques and a histopathological hallmark of this lesion type [147]. The resting 
state microglia in the healthy CNS tissue changes rapidly under detrimental conditions such 
as disruption of the blood brain barrier, alterations in neurotransmitter levels or when they 
detect danger signals from damaged cells [32, 137]. This activation of microglia together with 
a tremendous influx of macrophages may account for detrimental effects observed in CNS 
injury. For example in MS there is evidence that in some lesions microglia promote lesion 
development long before the infiltration of immune cells from the periphery [19]. 
Additionally, it is reported that microglia can kill oligodendrocytes [148-149] and that myelin 
is stripped off axons by macrophages/microglia in active MS lesions [150-151]. 
In contrast to this “negative” view of microglia/macrophage action in MS are data from 
studies showing that reduced microglia/macrophage activity has a detrimental outcome for 
remyelination, the endogenous repair process following demyelination [152]. Acute 
inflammation even enhances local remyelination in areas of chronic demyelination mainly 
due to the elevated response of macrophages/microglia [153]. Activated 
macrophages/microglia release a multitude of neurotrophic factors which might account for 
the beneficial effects observed in these studies. Furthermore the clearance of myelin debris, a 
significant hindrance in the process of remyelination, is mandatory for effective 
remyelination, as shown in studies using lysophosphatidylcholine or cuprizone to induce 
demyelination. In these studies depletion of macrophages resulted in impaired remyelination 
[154-155]. Taken together macrophages/microglia play a bilateral role during MS and in it´s 
various animal models. Understanding the fine balance between detrimental and beneficial 
effects of macrophages/microglia would significantly improve our knowledge of 
inflammatory and repair processes in the CNS and makes them promising targets for disease 
modifying treatments. 
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2. Scope of the study 
 
During the first part of this thesis I aimed to characterize the early effects of cuprizone-
treatment focusing on the role of oligodendrocytes as possible modulators of inflammatory 
processes. Therefore, I characterized histopathological changes in the corpus callosum of 
short-term (two days up to one week) cuprizone treated mice. I investigated the early 
oligodendrogliopathy, which is present shortly after initiating the cuprizone-diet and the 
paralleling activation of microglial cells. My main focus was on the question if 
oligodendrocytes actively contribute to microglia activation for example by the secretion of 
microglia activating factors (e.g. chemokines). 
 
As described in the introduction the progenitor status of oligodendrocytes is maintained by 
the growth factors FGF-2 and PDGFα. A finding I could confirm during the first part of this 
work. Since a balanced maintenance of oligodendrocyte proliferation and maturation is 
fundamental for repair mechanisms in the demyelinated CNS (i.e. remyelination). During the 
second part of this thesis I was interested whether FGF-2 and PDGFα may influence the gene 
expression of primary oligodendrocytes and the oligodendrocyte-like cell line OLN93. 
Therefore I investigated in a second part of the study, if treatment with FGF-2 and PDGFα 
changes the expression of oligodendrocyte marker genes in vitro and which pathways might 
be involved in this process. 
 
Recent and ongoing research in our laboratory focuses on the role of chemokines as possible 
modulators of inflammatory processes during demyelination. In the third part of the study I 
investigated two chemokines (i.e. CCL2 and CCL3) under demyelinating conditions, which 
have already been described to play important roles in the context of MS, as well as in animal 
models of MS (i.e. EAE and cuprizone). As mentioned in the introduction chemokines can 
have redundant functions and thus one chemokine might conceal an important disease 
mechanism of another chemokine. Therefore I generated a double knockout mouse of CCL2 
and CCL3. My work focused on the basic characterization of the mice together with a first 
five-week cuprizone trial. 
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3. Materials and Methods 
3.1 Mice and demyelination 
C57BL/6J mice were obtained from The Jackson Laboratory´s stock (000664) at Charles 
River (Sulzfeld, Germany) and served as controls for CCL2, CCL3, CCL2/3 and CXCL10 
knockout (ko; CCL2-/-, CCL3-/-, CCL2/3-/-, CXCL10-/-) mice. CCL2-/- and CCL3-/- single 
deficient mice were obtained from The Jackson Laboratory (B6.129S4-Ccl2tm1Rol/J, 
B6.129P2-Ccl3tm1Unc/J). CXCL10-/- deficient mice were kindly provided by Dr. U. Christen 
(Pharmazentrum Frankfurt/ZAFES, Klinikum der Goethe Universität, Frankfurt am Main, 
Germany [156]). CCL2/3-/- double deficient mice were generated by extensive cross breeding 
of CCL2 and CCL3 single knockout mice. Mice were kept under standard laboratory 
conditions according to the Federation of European Laboratory Animal Science Association’s 
recommendations. The procedures were approved by the Review Board for the Care of 
Animal Subjects of the district government (Nordrhein-Westfalen, Germany) and performed 
according to international guidelines on the use of laboratory mice. Demyelination was 
induced by feeding 8-week-old (19-21 g) male or 10-week-old female mice a diet containing 
0.2 % or 0.25 % cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma-Aldrich Inc., 
Germany) mixed into ground standard rodent chow (SNIFF Spezialdiäten, Germany) for the 
indicated period as published previously [34-35]. Control mice were fed ground standard 
chow. Details about sex, number of mice and the concentration of cuprizone used are 
indicated in the respective figure legends. 
 
3.2 Tissue preparation: transcardial perfusion and paraffin-embedding 
For histological and immunohistochemical studies, mice were transcardially perfused with 
2 % paraformaldehyde perfusion solution containing: 
 
100 ml Formaldehyde (37%, Roth, Germany) 
4.6 g NaH2PO4 (Roth, Germany) 
8 g Na2HPO4 (Roth, Germany) 
filled up to 1 L with A. dest. 
 
The pH was adjusted to 7.0-7.4 and the solution was filtered and cooled down to 4°C. Before 
perfusion, mice were intraperitoneally injected with 20 µl of Clexane (heparin, Sanofi-
Aventis, Germany) diluted 1:5 in phosphate buffered saline (PBS, Biochrom, Germany). The 
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mice were deeply anesthetized, fixed and the thorax opened using forceps and scissors. A 
small cut was placed in the right heart atrium and a small needle was inserted into the left 
heart ventricle to perfuse the mice with 20 ml cold perfusion solution with low pressure using 
a syringe. Afterwards 130 ml perfusion solution was applied at low undefined pressure using 
a drip. The tissue of interest was stored in perfusion solution over night at 4°C and prepared 
the day after for immediate embedding. 
Paraffin-embedding of mice tissue samples was performed by dehydration with several 
ethanol bathes of increasing concentration followed by incubation in xylene to eliminate 
ethanol residues. Finally, the tissue was incubated in paraffin wax, which was changed three 
times to eliminate xylene residues. The incubation times in increasing ethanol, xylene and 
paraffin were as follows: 
 
70 %  ethanol  2 × 40 min 
96 %  ethanol  3 × 40 min 
100 %  ethanol  1 × 40 min 
100 %  ethanol  2 × 60 min 
xylene   3 × 40 min 
paraffin    2 × 30 min 
paraffin   at least 2 days 
 
Incubation in ethanol and xylene was performed at room temperature under a fume hood and 
constant agitation. Paraffin incubation was performed in a 60°C incubator. The tissue samples 
were then embedded in paraffin using tissue molds and stored at 4°C. 
Embedded brains were coronary sectioned into 5 µm sections from approximately the levels 
215 to 275 (short-term cuprizone experiments with wild type, CCL2-/-, CCL3-/- and CXCL10-/- 
mice), 215 to 525 (characterization of CCL2/3-/- mice) and 255 to 295 (5 weeks cuprizone 
treatment with wild type and CCL2/3-/- mice) according to the mouse brain atlas of Sidman et 
al. (http://www.hms.harvard.edu/research/brain/atlas.html). 
For gene expression analyses, mice were transcardially perfused with ice-cold PBS, brains 
subsequently removed, and the entire corpus callosum (CC) was dissected from the cortex 
(Cx) using a stereomicroscopic approach [38, 157]. Tissues were immediately snap frozen in 
liquid nitrogen and kept at -80°C until further used. 
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3.3 Immunohistochemistry (IHC) and cell parameter quantification 
For IHC, paraffin sections were placed on advanced adhesive slides (Starfrost, Knittel Glas, 
Germany) and dried over night at 37°C. Sections were deparaffinized and rehydrated as 
follows: 
 
xylene   4 × 5 min 
100 % ethanol  3 × 3 min 
96 % ethanol   2 × 3 min 
70% ethanol   1 × 3 min 
A. dest.   1 × 3min 
 
Depending on the primary antibody used, heat induced epitope retrival (HIER) was performed 
in Tris/EDTA buffer pH 9 or citrate buffer pH 6. Some antibodies, however, did not need any 
HIER, and this step was thus omitted. 
 
Tris/EDTA buffer: 
- 1.21 g Tris-(hydroxymethyl)-aminomethan (Roth, Germany) 
- 0.37 g Ethylendiamintetraacetic acid (Roth, Germany) 
- 0.5 ml Tween®20 (Sigma-Aldrich, Germany) 
- filled up to 1 L with A. dest 
 
Citrate buffer: 
- 2.94 g Sodium citrate dehydrate (Sigma-Aldrich, Germany) 
- 0.5 ml Tween®20 (Sigma-Aldrich, Germany) 
- filled up to 1 L with A. dest. 
 
Sections were placed in the respective buffer and boiled using a microwave for 10 min. 
After HIER sections were cooled, washed three times in PBS and blocked with PBS 
containing 1 % normal horse, goat or donkey serum for 1 hour. Incubation with primary 
antibody was performed overnight at 4°C with the primary antibodies diluted in blocking 
solution. Primary antibodies, corresponding HIER and dilutions used in the study are given in 
Table 1. 
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Tab. 1 Primary antibodies used for IHC/ICC 
Antibody Host Directed against Dilution AGR Supplier cat. No. 
APC Mouse 
adenomatous polyposis 
coli 
(oligodendrocytes) 
1:200 Tris/EDTA Calbiochem, OP80 
CA2 
(used for 
ISH/IHC 
double 
staining) 
Rabbit carbonic anhydrase-2 (oligodendrocytes) 1:2000 None 
Dr. Said 
Ghandour, 
(University of 
Strasbourg, 
France) 
Caspase-3 Rabbit Activated caspase-3 (apoptotic cells) 1:300 Tris/EDTA 
Abcam 
Ab13847 
CNPase Mouse 
2´,3´-cyclic-nucleotide 
3´-phosphodiesterase 
(oligodendrocytes) 
1:250 None Abcam 
ab6319 
GFAP Rabbit 
glial fibrilary acidic 
protein 
(astrocytes) 
1:1000 Tris/EDTA Encore, RPCA-GFAP 
GFAP 
(used for 
ISH/IHC 
double 
staining) 
Rabbit 
glial fibrilary acidic 
protein 
(astrocytes) 
1:1000 None 
Millipore 
(Chemicon) 
AB5804 
IBA1 Rabbit 
ionized calcium binding 
adaptor molecule-1 
(microglia/ 
macrophages) 
1:500 
(used 
1:1000 for 
ISH/IHC 
double 
staining) 
Tris/EDTA Wako, 019-19741 
MAC3 Rat 
surface antigen MAC3 
(phagocytic 
microglia/macrophages) 
1:25 Tris/EDTA 
BD 
Pharmingen, 
550292 
OLIG2 Rabbit 
oligodendrocyte 
transcription factor 2 
(oligodendrocytes) 
1:2000 Tris/EDTA Millipore, AB9610 
PCNA Mouse 
proliferating cell nuclear 
antigen 
(proliferating cells) 
1:2000 Tris/EDTA Abcam, 
ab29 
PLP Mouse proteolipid protein (myelin) 1:500 None 
AbD Serotec, 
MCA839G 
 
After washing three times with PBS and blocking of endogenous peroxidase in 0.3 % 
hydrogen peroxide (in PBS) for 30 min, sections were washed three times in PBS and 
incubated with appropriate biotinylated secondary antibodies for 1 hour diluted in blocking 
solution. Sections were washed again three times, followed by peroxidase-coupled avidin-
biotin-complex for 1 hour according to the supplier’s recommendation (ABC kit, Vector 
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Laboratories). The di-amino-benzidine-reaction (DAB; DAKO Deutschland GmbH, 
Germany) was used to visualize peroxidase-avidin-biotin complexes according to the 
supplier’s recommendations. Sections were counterstained with standard haematoxylin to 
visualize cell nuclei if appropriate. Secondary antibodies and dilutions used are given in 
Table 2. Before mounting of slides in DEPEX (Serva, Germany), sections were dehydrated in 
bathes with increasing ethanol concentrations and xylene as follows: 
 
70 % ethanol   2 × 3 min 
96 % ethanol   2 × 3min 
100 % ethanol  3 × 3 min 
xylene   3 × 3 min 
 
Haematoxylin and eosin (HE) staining was performed on deparaffinized sections for 
evaluation of apoptosis using well defined morphological criteria such as condensed and 
fragmented cell nuclei [35, 158]. Sections were placed in haematoxylin solution for 30 s and 
blue color was developed under running tap water for 5 min. Thereafter, slides were placed in 
eosin solution for 30 s followed by increasing alcohol bathes and mounting in DEPEX as 
described above. 
 
For fluorescence double-labeling experiments, slides were deparaffinized, HIER was 
performed if appropriate and blocked with 5 % bovine serum albumin (BSA, Roth, 
Germany)/PBS for 1 hour and incubated overnight at 4°C with primary antibodies diluted in 
1 % BSA /PBS. After washing three times with PBS slides were incubated with Alexa Fluor 
488 anti-mouse and Alexa Fluor 568 anti-rabbit antibodies (1:500, Life Technologies, 
Germany) diluted in 1 % BSA/PBS for 2 hours followed by three washing steps in PBS. Cell 
nuclei were counterstained for 5 min with Hoechst 33342 (1:100,000 in PBS, Life 
Technologies, Germany). Slides were washed again in PBS and mounted with 
FluoPreserveTM mounting medium (EMD Biosciences, USA). 
DAB-stained sections were analyzed using a Nikon ECLIPSE 80i microscope. Fluorescence 
stained slides were analyzed with the Floid cell imaging station (Life Technologies, 
Germany). Z-stack and confocal images were captured using the LSM710 laser scanning 
microscope station (Carl Zeiss AG, Germany). 
For cell-parameter quantification, two consecutive sections per mice were evaluated in the 
medial and lateral parts of the CC and values averaged. Quantification in the Cx area was as 
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well performed on two consecutive sections in the layer 4 of the somatosensory Cx and the 
average calculated. Ionized calcium binding adaptor molecule-positive (IBA1+) microglia and 
glial fibrillary acidic protein-positive (GFAP+) astrocytes were only counted when a 
haematoxylin-stained nucleus was clearly visible. The area and the staining intensity of the 
region of interest was quantified using ImageJ 1.45 (National Institute of Health, USA) and 
cell numbers are given in cells per mm2. Counting of cells according to this procedure was 
performed twice by two independent, blinded examiners and results were averaged. 
Determination of microglial cell area was performed using ImageJ 1.45 and the auto-detect 
area tool. Approximately 10 randomly chosen microglial cells per section were measured in 
the medial CC at 400 x magnification by blinded examiners and the results averaged. 
 
Tab. 2 Secondary antibodies for IHC/ICC 
Antibody Host Directed against Dilution Supplier cat. No. 
Biotinylated 
anti-mouse IgG 
Horse mouse IgGs 1:50 Vector Lab. 
BA-2000 
Biotinylated 
anti-rabbit IgG 
Goat rabbit IgGs 1:50 Vector Lab. 
BA-1000 
Biotinylated 
anti-rat IgG 
Mouse rat IgGs 1:25 BD Pharmingen 
Anti-mouse 
Alexa Fluor 488 
Donkey mouse IgGs 1:500 Life Technologies, 
A21202 
Anti-rabbit 
Alexa Fluor 568 
Goat rabbit IgGs 1:500 Life Technologies, 
A11011 
 
3.4 Immunocytochemistry (ICC) 
For ICC, cells were seeded on poly-ornithine-coated glass coverslips, treated as indicated, 
fixed with 3.7 % formalin for 20 min at room temperature, washed three times with PBS, 
permeabilzed with 0.2 % Tween®20 (Sigma-Aldrich, Germany) in PBS for 10 min and 
blocked with 5 % BSA/PBS for 30 min. Coverslips were subsequently incubated with primary 
antibodies diluted in 1 % BSA/PBS overnight at 4°C. After washing three times with PBS, 
coverslips were incubated with secondary antibodies in 1 % BSA/PBS for 2 hours at room 
temperature. After 3 washing steps, cell nuclei were counterstained with Hoechst 33342 
1:100000 diluted in PBS. Coverslips were washed ones in distilled water and then mounted in 
FluoPreserveTM (EMD Biosciences, USA). Dilutions for primary and secondary antibodies 
used for ICC are given in Table 1 and 2, respectively. 
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3.5 Electron microscopy 
Electron microscopy (EM) was performed in collaboration with Prof. Werner Baumgartner 
(Department of Cellular Neurobionic, Institute for Biology II RWTH Aachen, 52056 Aachen, 
Germany) as published previously [159]. Two days cuprizone fed and control mice were 
perfused with EM perfusion buffer: 
 
EM perfusion solution: 
- 100 mM cacodylate pH 7.2 (Fluka, Germany) 
- 1.5 % formaldehyde (AppliChem, Germany) 
- 1.5 % glutaraldehyde (Fluka, Germany) 
- 5.8 g/ L NaCl 
 
Trimmed brain sections were post-fixed for 1 hour in 1 % (w/v) OsO4 (Fluka, Germany) in 
PBS, dehydrated and embedded in Epon 812 (Epon mix, Serva, Germany). Thin sections 
were cut, contrasted with uranyl acetate and lead citrate, and myelination of axons was 
analyzed with a Zeiss EM10C electron microscope. 
 
3.6 In situ hybridization (ISH) 
Fluorescence labeled ISH was performed using the QuantiGene® View RNA ISH tissue 
assay (Affymetrix, USA) according to the manufacturer’s protocol. Briefly, 5 µm paraffin-
embedded tissue slices were post-fixed for 60 min in 10 % formaldehyde, deparaffinized and 
boiled for 10 min in pretreatment solution. After washing in distilled water, slides were 
incubated in a wet chamber in protease solution for 20 min at 40°C (hybridization oven), 
washed with PBS and fixed again with 4 % formaldehyde for 5 min. After fixation and 
washing, the slides were incubated with the probe set hybridization mix directed against Plp, 
Cxcl10 or Ubiquitin (reference gene) for 3 hours at 40°C. Appropriate negative controls were 
incubated with probe set diluent only. After hybridization of target gene probes, slides were 
washed in washing buffer and signal amplification and probe labeling was performed 
according to the manual. For visualization, the slides were incubated with enhancer solution 
for 5 min followed by 30 min incubation with fast red substrate at 40°C. After washing once 
in PBS the slides were fixed in 4 % formaldehyde for 5 min, washed again in PBS, 
counterstained with Hoechst 33342 (1:100,000 diluted in PBS) for 5 min and mounted in 
FluoPreserveTM (EMD Biosciences, USA). 
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ISH with radioisotopic labeled riboprobes was performed in collaboration with Prof. Luc 
Valliéres (Department of Neurosciences, Laval University Hospital Research Center, Quebec 
G1V 4G2, QC, Canada) as described previously [160]. Two days cuprizone-treated and 
control mice were perfused with a buffer containing 4 % paraformaldehyde, 0.1 M 
sodiumtetraborate (Sigma, Germany) pH 9.5, post-fixed over night and send to Prof. Valliéres 
for further analysis. Riboprobes were synthesized from linearized plasmids containing a 
fragment of mouse Ccl2, Ccl3, or Cxcl10 cDNA. In some experiments, immunostaining for 
IBA1 (microglia marker), GFAP (astrocyte marker) or carbonic anhydrase-2 (CA2, mature 
oligodendrocyte marker) and in situ hybridization were sequentially performed on the same 
sections with modifications reported by Villeneuve and colleagues [160]. 
 
3.7 Cell culture and treatment 
All cells were kept at 37°C and 5 % CO2 in a humidified incubator. 
3.7.1 Primary cultures of glial cells were prepared from the brains of one to two day-old 
Wistar rats. Meninges were carefully removed from cerebral hemispheres and the tissue 
mechanically disrupted using a pipette. Single-cell suspensions were transferred to culture 
flasks (1 brain/75 cm2) and kept for 12-14 days in basal glia medium:  
 
- Dulbecco´s Modified Eagle Medium, (DMEM, Gibco, Life Technologies, Germany)  
- 10 % heat-inactivated fetal calf serum (FCS, PAA Laboratories GmbH, Germany)  
- 50 U/ml penicillin, and 50 µg/ml streptomycin (P/S) (Gibco, Life Technologies, 
Germany) 
 
The medium was replaced every other day. 
3.7.2 Oligodendrocyte precursor cells (OPCs) were isolated and further purified from the 
flasks after 12-14 days as described by Richter-Landsberg and Vollgraf with minor 
modifications [38, 161-162]. For OPC separation, medium was replaced, cells incubated for 1 
hour in the incubator and flasks were shaken for two hours at 100 rpm to remove cell debris 
and loosely attached microglia. Flasks were washed with pre-warmed PBS and incubated with 
fresh medium for 1 hour. Afterwards, OPCs were separated from the underlying astrocytic 
cell layer by vigorous shaking (for 16 hours at 240 rpm) at 37°C. The next day, the medium 
was collected, the flasks washed with pre-warmed PBS and medium and PBS were combined 
for centrifugation (10 min at 800 g). For differential adherence the cells were resuspended in 
20 ml basal glia medium and plated on uncoated 10 cm plastic petri-dishes for 30-45 min in 
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the incubator. During this procedure astrocytes and microglia attach to the plastic surface, 
whereas OPCs remain unattached (i.e. differential adherence). Afterwards the OPCs were 
harvested under slow movement of the plate with the medium and the cell number was 
counted using a Neubauer counting chamber. OPCs were replated on poly-ornithine-coated 
culture dishes (2 × 105 cells/ well of a 6-well plate) and kept for 2 hours in DMEM 
supplemented with 10 % FCS. Medium was then changed to serum free proliferation medium 
containing of: 
 
Basal primary oligodendrocyte medium: 
- DMEM  
- 1 × N2 supplement (Gibco, Life Technologies, Germany) 
- 10 nM Biotin (Sigma-Aldrich, Germany) 
- 0.1 % BSA (Roth, Germany) 
- 1 % P/S 
- 5 µg/ml  N-acetyl-L-cysteine (Sigma-Aldrich, Germany) 
Supplemented with: 
- 10 ng/ml human recombinant fibroblast growth factor 2 and platelet derived growth 
factor α (FGF-2, PDGFα, both PeproTech, Germany). 
 
To obtain highly purified and proliferating OPC cultures, cells were cultured under these 
conditions for 3 days and half of the medium was changed at the second day. On the third 
day, cells were treated as indicated or the medium was changed to a differentiation medium to 
induce mature oligodendrocytes (mOL) differentiation. Differentiation medium consisted of 
basal oligodendrocyte medium supplemented with: 
- 15 nM 3,3´,5-triiodo-L-thyronine (T3, Sigma-Aldrich, Germany)  
- 10 ng/ml rat recombinant ciliary neurotrophic factor (CNTF, PeproTech, Germany). 
 
Cells were allowed to differentiate for 3 days until morphological changes (high number of 
cellular processes) were clearly visible [163]. Purity of primary oligodendrocyte cultures was 
determined by means of immunocytochemistry. Cultures contained 0.3676 ± 0.3673 % IBA+ 
microglia and 8 ± 1.225 % GFAP+ astrocytes (values are given as arithmetic mean of n = 3 
experiments ± SEM). 
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3.7.3 Rat OLN93 cells were a kind gift from Prof. Christiane Richter-Landsberg (Carl von 
Ossietzky Universität Oldenburg, Institut für Biologie und Umweltwissenschaften, AG 
Molekulare Neurobiologie/ Neurochemie, Oldenburg, Germany [164]). Cells were seeded in 
uncoated 6-well plates at a density of 1.5 × 105 cells per well and cultured in basal glia 
medium supplemented with 1 % sodium pyruvate [164]. 
Primary rat oligodendrocytes or OLN93 cells were stimulated with either 100 ng/ml 
lipopolysaccharide (LPS, L4391, Sigma-Aldrich, Germany.), 100 U/ml rat recombinant 
interferon-γ (IFNγ, Peprotech, Germany for primary oligodendrocytes and ELISA or Hycult, 
Netherlands for migration assay), 100 ng/ml tumor necrosis factor α (TNFα, Invitrogen, 
Germany), 10 µM H2O2 (Roth, Germany) or 1 mM glutamate (Roth, Germany) for 24 hours 
in serum-free DMEM/F12 medium containing: 
 
DMEM/F12 medium: 
- DMEM/F12 medium (Gibco, Life Technologies, Germany)  
- 1 × N2 supplement 
- 0.48 mM L-glutamine (Gibco, Life Technologies, Germany) 
- 5.3 µg/ml D-glucose (Roth, Germany) 
- 100 µg/ml P/S 
 
Supernatant was collected, filtered through a 0.45 µm filter (VWR, Germany) and stored at -
80°C until used. 
3.7.4 Mouse embryonic stem cell-derived microglial cells (EsdM [165]) were a kind gift from 
Prof. Harald Neumann (Neural Regeneration Group, Institute of Reconstructive 
Neurobiology, University of Bonn, 53127 Bonn, Germany). Cells were cultivated in serum-
free DMEM/F12 medium. Treatment of microglial cells for gene expression studies was 
performed in collaboration with Dr. Clara Beutner and Prof. Harald Neumann (Neural 
Regeneration Group, Institute of Reconstructive Neurobiology, University of Bonn, 53127 
Bonn, Germany). 2 × 105 cells were seeded in a 6-well plate and stimulated for 24 hours with 
10 ng/ml mouse recombinant CXCL10 or supernatant from IFNγ stimulated OLN93 cells. To 
block CXCL10-induced gene expression, an anti-rat CXCL10 antibody (1 µg/ml, Peprotech, 
Germany) was added to the supernatants before incubation with microglial cells. Medium 
with or without IFNγ and control IgGs served as negative controls for OLN93 supernatants 
and blocking experiments, respectively. 
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3.7.5 Primary mouse astrocyte cultures were prepared from the brains of one to two day-old 
wild type or CCL2/3-/- mice as published previously [166]. Briefly, meninges were carefully 
removed from cerebral hemispheres and the tissue mechanically disrupted using a pipette. 
Single-cell suspensions were transferred to culture dishes (3 brains/ 10 cm dish) and kept in 
basal glia medium until confluency was reached. The medium was replaced every other day. 
Before starting the experiment, cells were subcultured 1:10 in fresh 10 cm dishes to minimize 
microglial contamination and grown till 80-90 % confluency. For treatment cells were seeded 
into 6-well plates grown to 80 % confluency and treated with 1-10 µg/ml LPS for 24 hours. 
3.7.6 Isolation of mouse peritoneal macrophages was performed from adult wild type and 
CCL2/3-/- mice. Mice were killed by cervical dislocation and the abdominal skin carefully 
removed leaving the peritoneum intact. 5 ml of PBS containing 3 % FCS was injected with a 
25 gauge needle into the peritoneal cavity. After gently massaging the abdominal walls for a 
few minutes the liquid was removed with a 25 gauge needle and placed in a falcon tube on 
ice. The peritoneal cavity was opened and the remaining liquid carefully removed with a 
syringe without aspirating blood. The number of isolated macrophages was approx. 106 cells 
per mouse. The suspension was centrifuged for 5 min at 400 g, washed once with PBS and 
resuspended in 10 ml RPMI (Gibco, Life Technologies, Germany) containing 10 % FCS and 
P/S. 2 × 105 cells were seeded per well of a 6-well plate and placed in the incubator. To 
remove dead cells and debris the medium was changed after 2 hours. After overnight 
incubation cells were treated with 1 µg/ml LPS for 2 hours in RPMI containing 10 % FCS and 
P/S. After treatment supernatant was removed and stored at -80°C until further used. 
 
3.8 Migration and Phagocytosis Assay 
Migration assays were performed in collaboration with Dr. Bettina Linnartz-Gerlach and Prof. 
Harald Neumann (Neural Regeneration Group, Institute of Reconstructive Neurobiology, 
University of Bonn, 53127 Bonn, Germany) following a published protocol [165]. Briefly, for 
the migration assay, 1 × 105 cells were seeded into the upper chamber of a transwell system 
(8 µm pore size, Merck Millipore, Germany) and the lower chamber was filled with medium 
containing 50 ng/ml recombinant mouse CXCL10 (R&D Systems) or supernatant of IFNγ-
stimulated OLN93 cells. To block CXCL10-induced microglia migration, an anti-rat CXCL10 
antibody (1 µg/ml, Peprotech, Germany) was added to the supernatants in the transwell 
system. Cells were incubated for 3 hours and migrated ones (cells on the lower side of the 
membrane) were counted using a Neubauer counting chamber. Results from direct CXCL10 
stimulation were normalized to results obtained from control wells without CXCL10. Results 
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from experiments with supernatants of OLN93 cells were normalized to results from 
corresponding wells containing either control EsdM medium or EsdM medium with IFNγ to 
exclude direct effects of IFNγ on microglial migration. 
For phagocytosis assays, 1.5 × 105 microglia were seeded into 6-well plates and stimulated 
with either 500 ng/ml LPS (positive control), 10 ng/ml CXCL10 (Peprotech, Germany) or 
LPS and CXCL10 in combination for 24 hours. Cells were then incubated with fluoresbrite 
polychromatic red 1.0 µm latex beads (yellow fluorescence under 545-610 nm filter, 
Polysciences, Inc., USA) for 1.5 hours. Flow cytometry was performed using the BD 
LSRFortessa cell analyzer (BD Biosciences, USA) and results were analyzed using FlowJo 
7.6.5 (Tree Star Inc., USA). Forward and sideward scatter were calibrated using unstimulated 
control cells. Fluorescence was then measured using the 488 nm laser with PE filter settings 
(575 nm) and on the basis of the fluorescence intensity of the cells, the amount of cells that 
phagocytised three or more beads was calculated. Therefore, all cells that represent the fourth 
peak (intensity ≥ 104) in the flow cytometry histogram or higher (compare Fig. 12A, Results 
4.1.7) were counted as phagocytic active cells and the percentage of all fluorescent cells was 
calculated. 
 
3.9 CellTiter Blue® Cell viability and CytoTox non-radioactive cytotoxicity assay 
Cell viability and cytotoxicity assays were performed according to the manufacturer’s 
protocol (Promega, USA). In brief, cells were treated as indicated and 30 µl of supernatant 
was used for lactate-dehydrogenase-based cytotoxicity assays. After 30 min incubation at 
room temperature in dark, lactate dehydrogenase (LDH) activity was monitored with a Tecan 
infinite 200 plate reader at 490 nm after addition of STOP-solution. Results were normalized 
to lysis control (100%) and subsequently expressed as percentage of control. The remaining 
cells were incubated with CellTiter Blue® solution for approximately 4 hours. Fluorescence-
intensity of resorufin in supernatants was then measured at 560/590 nm with a Tecan infinite 
200 plate reader, mean value of lysis control was subtracted from all samples as background 
and treated samples were normalized to control samples (100%). 
 
3.10 Microarray analysis 
Regulation of gene expression in different treatment groups was analyzed using Affymetrix 
GeneChip® whole mouse genome microarrays as published previously [167-169]. The array 
and subsequent statistical analysis was performed in collaboration with Dr. Bernd Denecke 
(Interdisciplinary Centre for Clinical Research (IZKF) Aachen, RWTH Aachen University, 
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52074 Aachen, Germany). Total RNA (n = 3 per treatment group) was isolated and the quality 
assessed using RNA NanoChips with the Agilent 2100 Bioanalyzer (Agilent, USA). The 
RNA integrity number (RIN) of the samples was in the range of 8.5 to 8.9. Samples with 
lower RIN were excluded from the array. Probes for the GeneChip® Mouse Gene 1.0 ST 
Arrays (Affymetrix, USA) were prepared and hybridized to the arrays according to the 
Affymetrix GeneChip® Whole Transcript Sense Target labeling Assay Manual. Raw image 
data were analyzed with AGCC (Affymetrix, USA) and gene expression intensities were 
normalized and summarized with RMA algorithm [170]. Only genes expressed more than 3-
fold compared to array internal negative controls were taken into consideration. Genes up-
regulated in the two days cuprizone-treated group versus the control group were identified 
according to the following criteria: expression of genes in cuprizone-treated samples is at 
least 2-fold higher compared to control samples and the adjusted p-value for changes in 
expression is smaller than 0.05. 
 
3.11 Real-time reverse transcriptase-polymerase chain reaction (rtRT-PCR) 
Gene expression levels were further investigated using the rtRT-PCR technology (BioRad, 
Germany), SensiMix SYBR Green (Bioline, Germany), and a standardized protocol as 
described previously [39, 166, 169]. Isolation of total tissue RNA was performed with the 
Qiagen Lipid tissue Kit (Qiagen, Germany) according to the manufacturer’s protocol. For cell 
culture experiments with OLN93 cells and primary oligodendrocytes, RNA was isolated with 
a standard phenol/chloroform extraction using PeqGold (PeqLab, Germany) and subsequent 
extraction of RNA with ice-cold Isopropanol. RNA was washed twice with 70 % ethanol, 
dried and resuspended in Rnase-free water. RNA isolation from microglial cells (EsdM) was 
performed using the Qiagen Rneasy mini Kit (Qiagen, Germany) according to the 
manufacturer’s protocol. RNA concentration and purity was measured using the OD260 and 
OD260/OD280 ratio, respectively. Reverse transcription was performed with the Invitrogen 
MMLV RT-Kit and random hexanucleotide primers (both Invitrogen, Germany) according to 
the supplier’s protocol. The PCR reactions were done in a reaction mixture containing: 
 
- 2 µl cDNA (1:10 diluted in DNAse-free water) 
- 2 µl Rnase-free water 
- 5 µl SensiMix SYBR Green (Bioline, Germany) 
- 0.5 µl of each sense and antisense primer (100 pmol/µl, Life Technologies, Germany) 
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Primer sequences and respective annealing temperatures are given in Table 3. PCR with the 
MyIQ rtPCR Detection System (BioRad, Germany) was performed under following 
conditions: 
 
- 10 min enzyme activation at 95°C 
- 40 cycles of: 
- 15 s denaturation at 95°C 
- 30 s annealing at individual temperatures 
- 30 s amplification at 72°C 
- 5 s fluorescence measurement at 80°C. 
 
Relative quantification was performed using the ∆Ct method, which results in ratios between 
target gene and a reference gene. Expression levels of the ribosomal RNA 18s (18s), 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) or Cyclophilin A (Cyca) were used as 
reference genes for mouse or rat samples as indicated in the figure legends. Constant 
expression of these reference genes under the given experimental conditions was routinely 
tested in our laboratory (not shown). In each run internal standard curves were generated by 
several fold dilutions of generated cDNA. The concentration of the target genes were 
calculated by comparing Ct values in each sample with Ct values of the internal standard 
curve. Finally, data were expressed as the ratio of the amount of each transcript versus the 
concentration of the reference gene. Melting curves and gel electrophoresis of the PCR 
products were routinely performed to determine the specificity of the PCR reaction (not 
shown). 
 
For semi-quantitative reverse transcriptase PCR (sqRT-PCR) a related protocol was used. The 
PCR reaction was done in a PCR reaction mix containing: 
 
- 1 µl cDNA (undiluted) 
- 1.25 µl 10 × PCR buffer (Bioline, Germany) 
- 0.38 µl MgCl2 (50nM, Bioline, Germany) 
- 0.25 µl dNTPs (10 nM, Bioline, Germany) 
- 0.25 µl of each sense and antisense primer (100 pmol/µl, Life Technologies, 
Germany) 
- 9.3 µl Dnase free water 
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PCR was performed under following conditions with the Eppendorf Mastercycler epgradient 
S (Eppendorf, Germany): 
 
- 3 min initial denaturation 95°C 
- 18-40 cycles of: 
- 40 s denaturation at 95°C 
- 40 s annealing at individual temperatures 
- 45 s amplification at 72°C 
- Followed by 2 min final elongation at 72°C 
 
Visualization of sqRT-PCR products was performed using 2 % agarosegel in 1 × TAE buffer 
with ethidium bromide and electrophoresis at 120 V for 40 min. Images were captured with 
the E-Box VX2 (Peqlab, Germany). 
 
Tab. 3. List of primers used for rtRT-PCR and sqRT-PCR 
Name Forward sequence 5´-3´ Reverse sequence 5´-3´ AT 
Ccl2 mouse TTA AAA ACC TGG ATC GGA ACC 
AA 
GCA TTA GCT TCA GAT TTA CGG GT 60°C 
Ccl3 mouse TTC TCT GTA CCA TGA CAC TCT GC CGT GGA ATC TTC CGG CTG TAG 62°C 
Cxcl10 mouse CCA AGT GCT GCC GTC ATT TTC GGC TCG CAG GGA TGA TTT CAA 60°C 
Cxcl10 rat CTC TCG CAA GAA CGG TGC GCT CAG CAC TGT GGC GAG TGG CTT 60°C 
Plp mouse & 
rat 
TGG CGA CTA CAA GAC CAC CA GAC ACA CCC GCT CCA AAG AA 56°C 
Mag2 rat TGA ACG AGA CAG AGA GGG AGT T CTG GGT GAT GTA GCA GAC AAT G 60°C 
Mbp mouse CCC AAA GAA TAA CTG GCA AGG C GAA GCT CGT CGG ACT CTG AG 56°C 
Mbp rat CCA TCC AAG AAG ATC CCA CA CCT GTC ACC GCT AAA GAA GC 59°C 
Pdgfrα rat AGG CTT GGG GCT CAC TTT TT TCA GCG GCA CAA TCT TCT CA 61°C 
Cnpase rat TGG CGA AGA AGA TGG AAG TCA GTG GGT GAA GGA ACT GAT GGT T 61°C 
Cyca rat GGC AAA TGC TGG ACC AAA CAC TTA GAG TTG TCC ACA GTC GGA GAT G 62°C 
18s mouse CGG CTA CCA CAT CCA AGG AA GCT GGA ATT ACC GCG GCT 60°C 
18s rat CGT GAG AGT GTC TAA CGG G CGA GTC AGG CAT TTG GTC C 60°C 
inos mouse AAG CCC CGC TAC TAC TCC AT GCT TCA GGT TCC TGA TCC AA 60°C 
Tnfα mouse TCT TCT CAT TCC TGC TTG TGG AGG GTC TGG GCC ATA GAA CT 60°C 
Gapdh mouse ACA ACT TTG GCA TTG TGG AA GAT GCA GGG ATG ATG TTC TG 60°C 
 
3.12 Genotyping of CCL2/3-/- mice 
Genotyping was performed using sqPCR with genomic DNA isolated from a small piece of 
mouse tail. For DNA isolation, the Nucleospin tissue Kit (Macherey-Nagel, Germany) was 
used according to the manufacturer’s recommendations for rat and mouse tails.  
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The PCR reaction mix consisted of the following: 
 
- 2 µl genomic DNA (undiluted) 
- 0.125 µl of each primer (100 pmol/µl) 
- 0.125 µl BioXAct short DNA polymerase (Bioline, Germany) 
- 5 µl of 2 × PCR reaction buffer G, C or I (PCR optimization Kit Bioline, Germany) 
- Filled up to 10 µl with DNAse free water 
 
The primer sequences, product sizes and the buffer used for PCR reaction are given in Table 
4. PCR with 40 cycles and following visualization of PCR products was performed as 
mentioned above. 
 
Tab. 4 List of primers and buffers used for genotyping 
Name  Sequence 5´-3´ Size [bp] Buffer 
AT 
Ccl2 Mut s s GCC AGA GGC CAC TTG TGT AG 179 G 60°C 
Ccl2 WT s s TGA CAG TCC CCA GAG TCA CA 287  
Ccl2 
Common as as TCA TTG GGA TCA TCT TGC TG   
Ccl3 WT s s ATA CAA GCA GCA GCG AGT ACC 150 C 60°C 
Ccl3 WT as as ATG GCG CTG AGA AGA CTT G   
Ccl3 Mut s s TAA AGC GCA TGC TCC AGA CT 600 I 56°C 
Ccl3 Mut as as AGA GTC CCT CGA TGT GGC TA   
 
3.13 Enzyme-linked immunosorbent assay (ELISA) 
CCL2, CCL3 mouse and CXCL10 rat and mouse ELISA (Peprotech, Germany) were carried 
out according to the manufacturer’s protocol. Color development of the ABTS substrate 
(Sigma-Aldrich, Germany) was monitored with a Tecan infinite 200 plate reader at 405 nm 
with a wavelength correction at 650 nm. Chemokine release was normalized to total protein 
content of cell or brain lysate as determined with the Pierce BCA protein Assay (Thermo 
Fisher Scientific, Germany). For measurement of CXCL10 protein in protein lysates of mouse 
brain tissue, lysates were prepared from cortex and corpus callosum samples of control mice 
or mice treated for two days with cuprizone. Briefly, brains were homogenized in ice-cold 
PBS containing protease-inhibitor cocktail (Roche, Germany) using precellys® tissue 
homogenizer (15 s at 2000 rpm, PeqLab, Germany). Brain lysates were subsequently 
centrifuged twice for 20 min at 12000 g at 4°C and the supernatant was stored at -80°C until 
use. 
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3.14 SDS polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blot 
Protein levels were semi-quantitatively measured using SDS-PAGE and Western Blot 
analysis. Protein isolation was performed with RIPAplus buffer: 
 
RIPAplus buffer 
- 50 mM Tris HCl pH 8.0 
- 150 mM NaCl 
- 1 % NP-40 (Roth, Germany) 
- 0.5 % sodium deoxycholat (Roth, Germany) 
- 0.1 % SDS (Roth, Germany) 
- 1 × complete Mini protease inhibitor cocktail (Roche, Germany) 
- 200 nM Sodium orthovanadate (phosphatase inhibitor, Sigma-Aldrich, Germany). 
 
Lysed cells were centrifuged for 20 min at 12000 g at 4°C and supernatant was used for 
Pierce BCA protein assay and SDS-PAGE. 
For electrophoresis, 10 % Acrylamide (Rotiphorese gel 40, Roth, Germany) resolving gels 
and 5 % stacker gels were used. Gels were prepared as follows: 
 
Resolving gel: 
- 2 ml water 
- 1 ml 40 % Acrylamide 
- 1 ml resolving buffer (1.5 M Tris-OH, 0.4 % SDS, pH 8.8) 
- 40 µl 10 % APS (Sigma-Aldrich, Germany) 
- 4 µl Temed (Roth, Germany) 
 
After polymerization of the resolving gel, the stacker gel was casted as follows: 
 
Stacker gel: 
- 0.78 ml water 
- 0.16 ml 40 % Acrylamide 
- 0.31 ml stacker buffer (0.6 M Tris-Cl, 0.4% SDS, pH 6.8) 
- 12.5 µl 10 % APS 
- 1.2 µl Temed 
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After complete polymerization the gel was loaded with equal amounts of protein (5-10 µg) 
diluted in Laemmli buffer and denaturated for 5 min at 95°C. Proteins were separated in a 
Biorad SDS-PAGE system with SDS-run buffer pH 8.3 containing: 
 
SDS-run buffer: 
- 3 g Tris 
- 14.4 g Glycin 
- 1 g SDS 
- filled up to 1 L with A. dest. 
 
The gel was run at 80 V until proteins passed the stacker gel followed by 120 V for 
approximately 1.5 hours. 
For subsequent Western Blot analysis separated proteins were blotted onto a nitrocellulose 
membrane (Hybond, Amersham Biotech, UK) for 1 hour at 10 V using the following buffer: 
 
Transfer buffer: 
- 0.9 g Tris 
- 4.3 g glycin 
- 60 ml methanol 
- filled up to 300 ml with A.dest. 
 
The membrane was blocked after washing in Tris-buffered saline (TBS) with 5 % fat-free 
milk solution in TBS containing 0.05 % Tween20 ® (TBST) for 1 hour. The membranes were 
then incubated in primary antibodies diluted in 5 % BSA/TBST over night at 4°C, washed 
three times with TBST for 10 min and further incubated with appropriate secondary HRP-
coupled antibodies in 5% BSA/TBST for 2 hours at room temperature (see Table 5 for 
antibodies and dilutions). After three additional extensive washing steps with TBST and one 
wash with TBS visualization was performed with commercial enhanced chemoluminescence 
reagent kit (ABC Kit, Amersham Bioscience, UK) and exposure to X-ray film (Kodak, 
Germany). 
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Tab. 5 Primary and secondary antibodies used for Western Blot 
Antibody Host Directed against Dilution Supplier cat. No. 
CNPase Mouse 2´,3´-cyclic-nucleotide 3´-
phosphodiesterase 
(oligodendrocytes) 
1:500 Abcam 
ab6319 
P44/42 MAPK 
(Erk1/2) 
Rabbit total p44/42 MAP kinase 
(Erk1/Erk2) protein 
1:4000 Cell signalling 
4695S 
Phospho-
p44/42 MAPK 
(Erk1/2) 
(Thr202/ 
Tyr204) 
Rabbit p44/p42 MAP Kinase (Erk1/Erk2) 
when dually phosphorylated at 
Thr202 and Tyr204 of Erk1 
(Thr185 and Tyr187 of Erk2) or 
singly phosphorylated at Thr202. 
1:1000 Cell Signalling 
4370S 
Actin Rabbit Actin protein (cytoskeleton) 1:1000 Sigma 
A2066 
Anti-mouse 
HRP 
Rabbit mouse IgGs 1:1000 Abcam 
6728 
Anti-rabbit 
HRP 
Goat rabbit IgGs 1:4000 Biorad 
170-6515 
 
3.15 Statistical analysis 
Statistics were performed using absolute data. Intergroup differences were tested by ANOVA 
followed by Tukey’s or Bonferroni post hoc test using GraphPad Prism 5 (GraphPad Software 
Inc.) if not stated otherwise. All data are given as arithmetic means ± SEM. P-values are 
indicated as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. Number of experiments performed 
or mice used are given in the figure legends. 
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4. Results 
4.1 Oligodendrocyte-derived chemokine CXCL10 triggers microglial activation in the 
cuprizone animal model of multiple sclerosis 
 
4.1.1 Oligodendrocyte loss occurs early in the cuprizone model 
In a first set of experiments, I studied the temporal and spatial relationship of oligodendrocyte 
stress and early microglia activation using the cuprizone mouse model [34]. Mice were fed 
with cuprizone for two days or one week and brain sections were immunohistochemically 
analyzed. The principal region included in the study was the midline of the white matter tract 
corpus callosum (CC). 
Numerous apoptotic oligodendrocytes with condensed and/or fragmented nuclei in an 
interfascicular position were seen as early as two days after cuprizone feeding (arrow in Fig. 
2A). Several of the apoptotic nuclei were positive for the oligodendrocyte-specific 
transcription factor OLIG2 after one week cuprizone feeding (arrows in Fig. 2B). Apoptotic 
cells were absent in control mice. In addition double staining against activated caspase-3 and 
the myelin marker protein CNPase verified early oligodendrocyte apoptosis in this model 
(arrows in Fig. 2C). Apoptotic cells were virtually absent in control animals (data not shown). 
In parallel, I found a marked decrease in the number of adenomatous polyposis coli (APC)-
expressing mature oligodendrocytes (Fig. 2D). Immunohistochemical evaluation of 
myelination with antibodies directed against proteolipid protein (PLP) revealed that overt 
demyelination was not yet evident on the histological level (Fig. 2E). However, ultrastructural 
analysis revealed signs of a dying back oligodendrogliopathy with a splitting of the inner 
myelin lamella (Fig. 2F) in the CC of cuprizone-exposed mice. Such alterations were absent 
in control mice. Oligodendrocyte dysfunction was further confirmed by gene transcription 
studies (rtRT-PCR) of the myelin protein-encoding gene transcripts proteolipid protein (Plp) 
and myelin basic protein (Mbp). Plp and Mbp mRNA levels were reduced to 0.169 ± 0.016 
fold (Plp, mean ± SEM) and 0.14 ± 0.043 fold (Mbp, mean ± SEM), respectively, after 
cuprizone-treatment (Fig. 2G), which was confirmed using in situ hybridization (ISH) against 
Plp transcript (Fig. 2H). 
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Figure 2 Characterization of early oligodendrocyte stress in cuprizone-treated mice 
(A) HE-stained section of the midline of the corpus callosum (CC) in control (CO) mice and two days (2d) after 
initiation of the cuprizone diet. Note apoptotic oligodendrocytes in cuprizone-treated mice (see arrow). (B) Anti-
OLIG2 stained sections of the midline of CC in mice treated with cuprizone for one week (1w). Note OLIG2+ 
nuclei with typical morphological characteristics of apoptosis such as round, condensed and fragmented nuclei 
(see arrows). Scale bars A and B 10 µm. (C) Immunofluorescence double labeling for active caspase-3 (red) and 
CNPase (green). Caspase-3 positive cells can be found in between CNPase positive myelin fibers in 
interfascicular positioning, typical for oligodendrocytes. The lower picture in C shows higher magnification of 
the highlighted apoptotic cell. Scale bar 10 µm (upper panel), 5 µm (lower panel). Cell nuclei are stained with 
Hoechst 33342 (blue). (D) Quantification of APC+ oligodendrocytes in the midline of the CC of control (CO), 
two days (2d) and one week (1w) cuprizone-treated mice, respectively. Note lower numbers of APC+ cells after 
two days (273.3 ± 46.73, n = 4) and one week (148.0 ± 27.45, n = 4) compared to control (469 ± 55.32, n = 5) 
mice. (E) Myelin integrity was determined by immunohistochemistry with anti-PLP antibodies in the CC of 
control (CO), two days (2d) and one week (1w) cuprizone-treated mice. No gross abnormality in myelin was 
observed on the histological level. Scale bar 50 µm. (F) Electron microscopy of the midline of the CC was 
performed in control (CO) and two days (2d) cuprizone-treated mice. Note the splitting of innermost myelin 
lamella (arrow). Scale bars 1 µm; higher magnification 400 nm. (G) Gene transcript levels for Plp and Mbp were 
analyzed by rtRT-PCR from tissue obtained from the midline of the CC of control (CO), two days and one week 
cuprizone-treated mice. Values were normalized against the reference gene 18s and each bar represents the 
averaged fold induction over untreated controls. Note reduced mRNA levels of Plp and Mbp already two days 
after initiation of the cuprizone diet (Plp 0.14 ± 0.043, Mbp 0.169 ± 0.016, n = 4). (H) ISH against Plp transcript 
(red) on tissue sections from control (CO) and 2 days (2d) cuprizone-treated mice. Pictures show the midline of 
the CC. Note the strong expression of Plp transcript in control tissue located around nuclei (blue) in chain-like 
interfascicular positioning indicative for oligodendrocytes. Expression of Plp is strongly reduced after 2 days 
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curpizone treatment. Scale bar 10 µm. Male mice used. Values are given as arithmetic means ± SEM; * = p < 
0.05; ** = p < 0.01; *** = p < 0.001 (One-way ANOVA with Tukey’s post hoc test). 
37 
 
To study the relationship between oligodendrocyte stress and early microglia activation, the 
number of microglial cells was quantified in histological sections by antibodies directed 
against the microglia marker protein ionized calcium binding adaptor molecule-1 (IBA1). 
Microglial cell numbers gradually increased after initiation of the cuprizone-treatment (Figs. 
3A and 3B). At week 1, the number of IBA1+ cells was 6-times higher compared to controls. 
Besides microglia hyperplasia, microglia hypertrophy was detected at week one (Fig. 3C). In 
contrast, the number of glial fibrillary acidic protein (GFAP)-expressing astrocytes was not 
significantly altered till week one (Figs. 3D and 3E). 
In summary, short-term cuprizone-treatment resulted in early oligodendrocyte stress with 
concomitant microglial activation in the absence of overt demyelination. 
 
 
Figure 3 Characterization of early microglia and astrocyte responses 
(A) Immunohistochemistry with antibodies directed against the microglial protein IBA1. Note overt microgliosis 
in the midline of the CC in mice treated with cuprizone for two days or one week (2d and 1w). Scale bar 50 µm. 
(B) Quantification of IBA1+ cells within the CC revealed a strong increase of microglial cell numbers after two 
days (316.0 ± 10.87, n = 4) and one week cuprizone treatment (571.4 ± 65.62, n = 4) compared to controls (CO, 
48.29 ± 11.27, n = 5). (C) ImageJ based morphometrical quantification of microglial cell area within the CC 
demonstrates a beginning hypertrophy of IBA+ cells (CO: 129 ± 11.5, n = 3; two days: 179.1 ± 12.62, n = 4; one 
week: 379.8 ± 55.12, n = 4). (D) Quantification of GFAP+ astrocytes within the CC revealed no increase in 
astrocyte numbers at day two (81.09 ± 48.63, n = 4) or week one (33.47 ± 12.44, n = 4) compared to controls 
(CO, 90.87 ± 19.55, n = 5). (E) Immunohistochemistry with antibodies against the astrocytic protein GFAP in 
control (CO), two days (2d) and one week (1w) cuprizone-treated mice. Scale bar 50 µm. Male mice used. 
Values are given as arithmetic means ± SEM; * = p < 0.05; ** = p < 0.01; *** = p < 0.001 (One-way ANOVA 
with Tukey’s post hoc test). 
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4.1.2 Chemokines are dynamically regulated in cuprizone-treated mice 
In a next set of experiments I aimed to identify factors that are involved in early microglia 
activation. Total mRNA samples from the CC of mice fed with cuprizone for two days were 
analyzed using Affymetrix GeneChip® arrays. My analysis revealed an increased 
transcription of numerous pro-inflammatory genes, including genes coding for chemokines 
(Fig. 4A). From the 21 evaluated CCL-chemokines in the array, three were significantly 
increased, namely Ccl2 (Mcp1), Ccl3 (Mip1α) and Ccl7 (Mcp3); from the 13 evaluated 
CXCL- chemokines, only Cxcl10 (Ip10) displayed an increased expression after two days of 
cuprizone treatment. To confirm these results in more detail, rtRT-PCR was performed to 
specify the gene transcript levels of the three most induced chemokines Ccl2, Ccl3 and 
Cxcl10 (Fig. 4B). In line with the microarray data, mRNA levels of these three chemokines 
were increased after cuprizone exposure compared to untreated controls, with CXCL10 
revealing the most prominent fold change (~170 fold upregulation). Furthermore, higher 
levels of CXCL10 protein were detected by ELISA in brain lysates from cuprizone-treated 
animals compared to control mice (Fig. 4C). To examine the anatomical distribution of the 
cells expressing these chemokines, brain sections from cuprizone-treated mice were analyzed 
by ISH. Ccl2 mRNA was evenly distributed in the CC, including the myelin- and 
oligodendrocyte-rich deep cortical layers (arrows in Fig. 4D). Within the hippocampal 
formation, the polymorph layer of the dentate gyrus displayed some positive signals 
(arrowheads in Fig. 4D). Ccl2 signal intensity was weak in superficial cortical layers. In 
general, the hybridization signal for Ccl3 was much weaker. I detected some spots in the CC 
and adjacent Cx region (Fig. 4E). The strongest in situ hybridization signal was evident for 
Cxcl10. Strong expression was found in the CC, deep cortical layers and distinct hippocampal 
sub-regions, such as the polymorph layer of the dentate gyrus (arrowheads in Fig. 4F) or the 
stratum oriens and radiatum of the hippocampal cornu ammonis region (arrows in Fig. 4F). 
Remarkably, no Cxcl10 signal was observed in the neuronal granule cell layer of the dentate 
gyrus or the pyramidal layer of the cornu ammonis (stars in Fig. 4F), suggesting that neurons 
are not the major source of CXCL10 in this animal model. In summary, I found a selective 
upregulation of CXCL10, CCL2 and CCL3 chemokines in response to cuprizone-induced 
oligodendrocyte stress, and I assume that these chemokines might orchestrate the observed 
concomitant microglia attraction/activation. 
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Figure 4 Gene transcription and protein expression of chemokines in cuprizone- treated mice 
(A) Evaluation of whole mouse genome Affymetrix GeneChip® array shows that Ccl2, Ccl3, Ccl7 and Cxcl10 
transcripts are up-regulated in the CC after two days (2d) cuprizone exposure. Values are given as fold change 
over control. Hybridization signals for each mice and relative transcription levels (fold change = cuprizone vs. 
control), together with corresponding p-values are presented in the table (n = 3 mice per group). (B) mRNA 
expression levels of Ccl2, Ccl3 and Cxcl10 after two days (2d) cuprizone-treatment (fold induction over control: 
Ccl2: 29.74 ± 2.98; Ccl3: 15.54 ± 1.57; Cxcl10: 180.7 ± 17.44, n = 4), determined by rtRT-PCR. Note the strong 
upregulation of Cxcl10 expression (~170 fold; unpaired t-test with Welch’s correction). (C) CXCL10 protein 
levels in homogenized brain samples were determined by ELISA in control (CO) and two days cuprizone-treated 
mice (CO: 0.189 ± 0.0177; two days: 0.28 ± 0.024; n = 3, unpaired t-test). ELISA results were normalized 
against 1 mg total protein. (D-F) Dark-field photographs of in situ hybridization-labeled brain sections (two days 
cuprizone) for the respective chemokines Ccl2 (D), Ccl3 (E), Ccxl10 (F) taken at the level of the dorsal 
hippocampus (Hip). Scale bar 300 µm. Hybridization signals are shown as white grains. (D) Arrows mark the 
deep cortical layer 6, arrowheads the hippocampal polymorph layer of the dentate gyrus. (F) Arrows indicate 
strati oriens and radiatum of the hippocampal cornu ammonis region, arrowheads the polymorph layer of the 
dentate gyrus. Note that a signal is neither observed in the stratum granulare nor in the neuronal granule cell 
layer of the dentate gyrus or the pyramidal layer of the cornu ammonis (stars in F). Male mice used. Values are 
given as arithmetic means ± SEM; * = p < 0.05; ** = p < 0.01. 
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4.1.3 CXCL10- but not CCL2- or CCL3-deficient mice display less severe early microglia 
activation 
To examine whether chemokines contribute to early microglia activation in this model, 
CCL2-/-, CCL3-/- and CXCL10-/- mice were fed cuprizone for one week, and the extent of 
microgliosis was determined in IBA1-stained sections. While numbers of IBA1+ microglia 
were comparable in CCL2-/-, CCL3-/- and wild type animals, a ~ 40% reduction in the number 
of IBA1+ cells was found in CXCL10-deficient mice (Figs. 5A-C). In detail, the number of 
microglia was reduced in the CC from 448.131 ± 15.53 cells in wild type mice to 
285.816 ± 18.33 cells in the CXCL10-/- mice (Fig. 5C). Thus, CXCL10, but not CCL2 or 
CCL3, regulates early microgliosis in this model. 
 
 
Figure 5 Cuprizone-induced microglia activation in chemokine deficient mice  
(A) Anti-IBA1-immunostaining of the CC in control (CO) and one week cuprizone-treated wild type (WT) mice. 
(B) Sections of the midline of the CC stained with anti-IBA1 antibodies in CCL2-/-, CXCL10-/- and CCL3-/- mice 
after one week cuprizone exposure. Scale bar 50 µm. (C) Quantification of IBA1-expressing cells within the CC 
of wild type (WT) and knockout mice (CCL2-/-, CXCL10-/-, CCL3-/-) after one week cuprizone exposure 
(CO = wild type without treatment). All cuprizone-treated groups show increased numbers of IBA1+ microglia 
within the CC compared to control mice. Note reduced microgliosis in CXCL10-/- (285.8 ± 18.33, n = 11) 
compared to wild type mice (448.1 ± 15.53, n = 31). Male mice used. Values are given as arithmetic means ± 
SEM, * = p < 0.05; *** = p < 0.001 (One-way ANOVA with Tukey’s post hoc test). 
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4.1.4 CXCL10 is expressed and secreted by oligodendrocytes 
Oligodendrocytes have been suggested to modulate neuroinflammatory processes in the brain 
of MS patients [33, 171]. To examine whether oligodendrocytes can be a source of CXCL10 
in vitro, I analyzed brain sections from cuprizone-treated mice labeled for Cxcl10 mRNA by 
in situ hybridization and analyzed the tissue in the CC for cells with typical oligodendrocyte 
distribution (i.e. cells in chain-like formation in interfascicular positioning). As shown in 
Figure 6, Cxcl10 mRNA was detected in cuprizone-treated mice in cells with typical 
oligodendrocyte morphology (Fig. 6A arrowheads, Fig. 6C higher magnification). However 
Cxcl10 positive cells were found that did not display typical oligodendrocyte distribution, but 
may likely be astrocytes or microglial cells (Fig. 6A arrow, Fig. 6D higher magnification). No 
Cxcl10 mRNA expression was found in control mice (Fig. 6B). Furthermore, co-localization 
experiments with Cxcl10 ISH and subsequent immunohistochemistry against different cellular 
markers was performed (Fig. 7). Cxcl10 mRNA co-localized with the oligodendrocyte marker 
protein carbonic anhydrase-2 (CA2) (Fig. 7A) but neither with the microglia marker IBA1 
(Fig. 7B), the astrocyte marker GFAP (Fig. 7C) nor the endothelial marker CD31 (Fig. 7D). 
Nevertheless, the CA2+ cells did not display typical oligodendrocyte morphology. Taken 
together oligodendrocytes are a likely source of Cxcl10 expression in the cuprizone model 
and may thus play important roles in microgliosis and lesion development. 
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Figure 6 Cxcl10 mRNA is expressed in oligodendrocyte-like cells (A) In situ hybridization for Cxcl10 mRNA in 
four days cuprizone-treated male mice (4d). Arrowheads indicate cells with typical oligodendrocyte-like 
morphology e.g. chain-like formation in interfascicular positioning in the lateral corpus callosum. Cxcl10 mRNA 
was also detected in cells with non-oligodendrocyte-like spatial distribution (arrow). Scale bar 50 µm. Both cell 
types are shown in higher magnification in (C) and (D). Scale bar 15 µm. Note that the hybridization signal for 
Cxcl10 (red dots) can be found both, in the perinuclear compartment as well as in cell processes. Cell nuclei 
were counter stained with Hoechst 33342. (B) Cxcl10 expression in control mice. Note that there is no signal for 
Cxcl10 mRNA in untreated mice. Scale bar 50 µm.  
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Figure 7 Cxcl10 is expressed by oligodendrocytes in cuprizone- treated mice 
(A) Double labeling experiments for Cxcl10 mRNA (black dots) and the oligodendrocytes marker protein 
carbonic anhydrase-2 (CA2), the microglial marker protein IBA1, the astrocyte marker protein GFAP or the 
endothelial marker CD31, of male mice treated for two days with cuprizone. Scale bar 50 µm. Cells indicated by 
inserts in the left pictures are shown in a higher magnification on the right (brown, immunoperoxidase staining). 
Scale bar 10 µm. Note that Cxcl10 mRNA co-localizes in the CC with the oligodendrocyte marker CA2, but not 
with the marker proteins for microglia/macrophages, astrocytes or endothelial cells. 
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To further understand the relationship between oligodendrocyte stress and CXCL10 
expression, I performed cell culture experiments with primary rat oligodendrocytes and the 
oligodendrocyte cell line OLN93. Primary oligodendrocytes were purified from rat pups and 
cultured either in the presence of the growth factors FGF-2 and PDGFα to obtain 
oligodendrocyte precursor cells (OPCs) or in the presence of triiodo-L-thyronine (T3) and 
ciliary neurotrophic factor (CNTF) to obtain mature oligodendrocytes (mOL). As 
demonstrated via immunocytochemistry and semi-quantitative reverse transcriptase-
polymerase chain reaction (sqRT-PCR), this culture protocol results in either highly enriched 
OPCs (low Cnp = 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, Plp and Mbp mRNA levels; 
bi-polar morphology) or mature oligodendrocytes (low Pdgfra mRNA expression levels; 
ramified morphology with membrane formation; Fig. 8A). The stimulation of 
oligodendrocytes with interferon-γ (IFNγ) in non-cytotoxic concentrations, as determined by 
metabolic activity and lactate-dehydrogenase (LDH) release, resulted in a significant increase 
in CXCL10 protein levels in the cell culture supernatant (Fig. 8B). The extent of IFNγ-
induced CXCL10 release was comparable in OPCs and mOL. In line with my findings using 
primary cultures, IFNγ-stimulated OLN93 cells up-regulated CXCL10 at the mRNA (Fig. 8C) 
and protein levels (Fig. 8B/D). CXCL10 expression was also stimulated by the pro-
inflammatory molecules lipopolysaccharide (LPS) and tumor necrosis factor-α (TNFα), 
although to a lesser extent than IFNγ, but not by glutamate and hydrogen peroxide (Fig. 8D). 
Taken together my results clearly show that oligodendrocytes release CXCL10 in vitro under 
inflammatory conditions. 
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Figure 8 Stressed oligodendrocytes express CXCL10 in vitro 
(A) Primary rat oligodendrocyte cultures were either cultured in the presence of growth factors (FGF-2 and 
PDGFα) or triiodo-L-thyronine and CNTF to obtain oligodendrocyte progenitor cells (OPCs) or mature 
oligodendrocytes (mOL), respectively. Note the stronger expression of CNPase and the highly branched 
morphology of mOLs compared to OPCs. Scale bar 50 µm (left panel) or 5 µm (right panel). Sq-RT-PCR 
confirmed induction of myelin-associated genes (Plp, Mbp and Cnpase) in mOLs and lower expression of the 
OPC-marker gene Pdgfra. (B) CXCL10 protein levels in the supernatant of cultured OPCs, mOL cells and the 
rat oligodendrocyte cell line OLN93 treated with IFNγ for 24 hours. ELISA results were normalized against 
whole cell protein. Results obtained from primary-cultured OPCs and mOL were analyzed with one-way 
ANOVA followed by Tukey’s post hoc test and compared to respective controls. Results obtained from OLN93 
cells were analyzed with unpaired t-test with Welch’s correction. ** = p < 0.01. (C) Sq-RT-PCR was performed 
from cultured OLN93 cells either untreated or treated with IFNγ for 24 hours. Note the increased level of Cxcl10 
mRNA in IFNγ-treated OLN93 cells. The reference gene Cyclophilin A (Cyca) served as an internal control. (D) 
CXCL10 protein levels in the supernatant of cultured rat OLN93 cells treated with IFNγ, LPS, TNFα, H2O2, or 
glutamate. Note increased CXCL10 levels after stimulation with inflammatory cytokines and LPS, 
predominantly after IFNγ stimulation (CO: 3.3 ± 0.63,  IFNγ: 8.23 ± 1.2). ELISA results were normalized 
against whole cell protein. Values are given as arithmetic means ± SEM. ** = p < 0.01 (One-Way ANOVA with 
Tukey´s post hoc test). 
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4.1.5 CXCL10 does not affect mature oligodendrocyte cell death 
Recently, it has been reported that cultured oligodendrocytes die when exposed to CXCL10 in 
a concentration-dependent manner [172]. The lower extent of microglia activation I found in 
CXCL10-/- mice after cuprizone-treatment might simply be due to less severe oligodendrocyte 
loss in the absence of CXCL10. To investigate, whether CXCL10 influences oligodendrocyte 
death during cuprizone-treatment, the number of oligodendrocytes was quantified in the CC 
of wild type and CXCL10-/- mice after one week of cuprizone exposure. As shown in Fig. 9A, 
the cuprizone-induced loss of oligodendrocyte transcription factor 2-expressing (OLIG2) 
oligodendrocytes was comparable between both genotypes. In line with these findings, the 
number of apoptotic cells (as determined in HE-stained sections) was not significantly 
different in both strains (Fig. 9B). Furthermore, treatment of primary oligodendrocyte cultures 
(OPCs and mOL) with recombinant CXCL10 for 24 hours did not induce cell death as 
determined by LDH release (Fig. 9C). Thus, CXCL10 is not a master regulator of 
oligodendrocyte loss, at least in the applied model(s). 
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Figure 9 CXCL10 does not affect oligodendrocyte apoptosis 
(A) Anti-OLIG2 stained sections of the midline of CC in control (CO), wild type (WT) and CXCL10-/- mice 
after 
one week of cuprizone exposure. Scale bar 50 µm. Note that wild type (740.4 ± 94.75, n = 17) and CXCL10-/- 
(513.2 ± 55.6, n = 12) mice showed similar reduced cell numbers compared to control mice (1331 ± 91.49, 
n = 14). (B) Evaluation of apoptotic cells in HE-stained sections within the CC one week after cuprizone-
treatment. Scale bar 10 µm. Note that no significant difference is evident between wild type (69.34 ± 14.27, 
n = 11) and CXCL10-/- (102.1 ± 9.89, n = 12) mice compared to control mice (18.33 ± 7.92, n=5). (C) Primary 
cultures of rat OPCs and mOL were treated with recombinant CXCL10 for 24 hours. Note that treatment of 
primary rat oligodendrocyte cultures with CXCL10 (1 ng/ml to 100 ng/ml, OPC = oligodendrocyte precursor 
cell, mOL = mature oligodendrocyte) did not induce cell death as determined by LDH release. Male mice used. 
Values are given as arithmetic means ± SEM; ns = not significant (One-way ANOVA with Tukey’s post hoc 
test). 
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4.1.6 CXCL10 does not regulate microglia proliferation 
The lower number of IBA1+ cells found in CXCL10-/- mice (compare Fig. 5C) might be due 
to a reduction of microglia attraction (i.e. chemotaxis) or proliferation. To address this 
question, brain sections from wild type and CXCL10-/- mice were double-stained for the 
proliferation marker proliferating cell nuclear antigen (PCNA) and the microglia marker 
IBA1. Representative pictures of the staining are shown in Figure 10A. Note that CXCL10-/- 
mice show less IBA1+ and PCNA+ cells as well as double positive cells compared to wild 
type mice. To determine if CXCL10 in fact promotes the proliferation of microglial cells, I 
normalized the number of proliferating microglia (double positive for IBA1 and PCNA) to the 
number of total microglia (IBA1+) in each mouse. Thus I excluded that the differences seen 
are due to lower total microglia numbers in CXCL10-/- mice. Interestingly, the percentage of 
proliferating microglia, out of the total microglia population was comparable in WT and 
CXCL10-/- mice (Fig. 10B; ~50%). Additional in vitro experiments showed that CXCL10 
treatment does not result in increased metabolic activity in microglial cells, indicating that 
CXCL10 does not induce microglia proliferation in vitro (Fig. 10C). My in vivo and in vitro 
data thus indicate that CXCL10 does not directly affect microglia proliferation although the 
overall number of microglial cells is reduced in CXCL10-/- mice. 
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Figure 10 CXCL10 does not increase cuprizone-induced microglia proliferation 
(A) Anti-IBA1 (red) and anti-PCNA (green) stained sections of male wild-type and CXCL10-/- mice CC after 
one week cuprizone-treatment (arrowheads indicate double positive cells; nuclei are marked in blue). 
Immunostaining of IBA1 as well as PCNA was reduced in CXCL10-/- mice. Scale bar 50 µm. (B) Quantification 
of proliferating microglia (IBA+ and PCNA+ cells) in the CC of wild type and CXCL10-/- mice. Values are 
normalized to total IBA1+ microglia present in the analyzed region of the corresponding mice. No significant 
difference was observed in the percentage of double positive cells between wild type (52.21 ± 3.48) and 
CXCL10-/- mice (47.42 ± 5.8 unpaired t-test). (C) Treatment of cultured mouse microglial cells (ESdM) with 
CXCL10 for 24 hours. Note that CXCL10 did not change the metabolic activity of cultured microglial cells as 
determined by the CTB assay (One-Way ANOVA with Tukey´s pot hoc test). Values are given as arithmetic 
means ± SEM. 
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4.1.7 CXCL10 induces microglia attraction and activation, but not phagocytosis 
In further experiments, I addressed the question, whether CXCL10 plays a role in microglia 
attraction and activation. For this part of the study, I used a microglial cell line for all 
following experiments [165]. First, pro-migratory effects of CXCL10 on microglial cells were 
assessed. Both, recombinant CXCL10 and the supernatants of IFNγ-treated OLN93 cells 
induced directed microglial cell migration (Fig. 11A). To investigate whether CXCL10 is the 
key molecule leading to microglial attraction, a CXCL10-neutralizing antibody was added to 
the supernatant of the oligodendrocytes. As shown in figure 11A, oligodendrocyte-induced 
microglia migration was completely blocked by the addition of the CXCL10 neutralizing 
antibodies. 
The effect of CXCL10 on microglia polarization (i.e. pro-inflammatory phenotype, M1) was 
tested by rtRT-PCR after a 24 hours treatment period. Recombinant CXCL10 induced 18-fold 
and 7-fold increases in the expression of inos and Tnfα mRNAs, respectively (Fig. 11B). 
These effects were blocked by co-incubation with anti-CXCL10 antibodies (not shown). 
Furthermore, Cxcl10 expression was also increased, indicating a positive-feedback 
mechanism (Fig. 11B). To verify that stressed oligodendrocytes could actually induce a pro-
inflammatory phenotype in microglia, cultured microglia were stimulated with the 
supernatant of oligodendrocytes exposed to IFNγ for 24 hours. These experiments showed an 
induction of inos and Tnfα mRNA expression in microglia (Fig. 11C, checked bar), whereas 
the addition of CXCL10 neutralizing antibodies reverses this effect (Fig. 11C, striped bar). 
Cells incubated in the presence of unspecific IgGs served as a negative control. These results 
indicate that IFNγ-stimulated oligodendrocytes induce a pro-inflammatory microglial 
response which is in large part mediated by CXCL10 protein. 
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Figure 11 CXCL10 induces chemotaxis and a M1 phenotype in microglial cells  
(A) In vitro migration two chamber assay of cultured microglial cells (ESdM). Note that recombinant CXCL10 
(50 ng/ml) induced directed migration of microglial cells (144.7 ± 11.18) compared to negative control 
(microglia medium without stimulus, 100 ± 5.38) and undirected control (50 ng/ml CXCL10 in upper and lower 
chamber, 49.53 ± 10.7). Furthermore, supernatant from IFNγ-treated OLN93 cells (supernatants) induced a ~ 3 
fold increase in migration activity (311.6 ± 80.87) compared to untreated control conditions (supernatant from 
untreated OLN93 cells 118.6 ± 13.03). This effect was completely blocked by a pre-incubation step with anti-
CXCL10 antibodies (124.5 ± 24.14). Results from supernatants were normalized to corresponding negative 
controls containing microglia medium with or without IFNγ, to exclude direct effects of INFγ. Data are 
presented as means ± SEM of n = 7 independent experiments. Differences between groups were tested using 
ANOVA followed by post hoc Bonferroni. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (B) rtRT-PCR of 
microglial cells stimulated with CXCL10 for 24 hours. Note the induction of inos, Tnfα and Cxcl10 transcripts in 
CXCL10-stimulated microglia. (C) rtRT-PCR of microglial cells stimulated for 24 hours with supernatant 
(OLN93 supernatant) of untreated or IFNγ-treated OLN93 cells pre-incubated with anti-CXCL10 or control IgG. 
Stimulated microglia exhibited increased gene transcription of inos and Tnfα. This effect was partially 
neutralized with CXCL10 specific antibodies. In both experiments, values are presented as arithmetic means ± 
SEM and were normalized against a reference gene (Gapdh) and expressed relative to controls, cultured in 
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standard microglia medium (n = 3 independent experiments). Differences between groups were tested using 
ANOVA followed by Bonferroni. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; ns = not significant. 
Since phagocytosis is another cardinal function of microglia, I examined the effect of 
recombinant CXCL10 on the ability of microglia to phagocytose polystyrene latex beads by 
flow cytometry [165]. As a positive control, I used LPS which induced a 2-fold increase of 
microglial phagocytosis activity. I found that CXCL10 did not affect phagocytosis neither 
under basal conditions nor after LPS stimulation (Figs. 12A and B). These in vitro results 
indicate that CXCL10 does not modulate microglia phagocytosis. To verify these findings in 
vivo, the CC of wild-type and CXCL10-/- mice were stained for the lysosomal-associated 
membrane protein 2 (MAC-3/LAMP-2) which is a reliable marker for late stage lysosomes 
and phagocytosis [173-174]. The amount of MAC-3 positive cells was very small in both 
strains after cuprizone-treatment although higher compared to control mice (Fig. 12C). 
Statistical evaluation was therefore difficult and I assume that phagocytosis is not a major 
feature of microglial cells early after cuprizone-treatment. However, this finding is in line 
with my in vitro experiments as I did not see remarkable differences between wild type and 
CXCL10-/- mice. Taken together, my results indicate that CXCL10, secreted by stressed 
oligodendrocytes, induces microglia chemotaxis and the induction of a pro-inflammatory 
(M1) phenotype but does not regulate microglial phagocytosis and proliferation. 
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Figure 12 CXCL10 does not induce phagocytosis in microglial cells in vivo nor in vitro 
(A) Flow cytometry histograms show representative results obtained with the beads phagocytosis assay. Only 
cells that phagocytized 3 or more beads were counted as phagocytically active microglial cells (ESdM). Details 
on calculation are given in the materials and methods section. Numbers in the histograms indicate the percentage 
of phagocytic active microglial cells. CO: untreated microglia; LPS: microglia treated for 24 hours with 500 
ng/ml LPS; CXCL10: microglia treated for 24 hours with 10 ng/ml CXCL10; LPS/CXCL10: microglia treated 
for 24 hours with both, 500 ng/ml LPS and 10 ng/ml CXCL10. (B) Quantification of phagocytic activity of 
microglial cells. Note that CXCL10 does not change the phagocytic activity of microglial cells, while LPS 
increased the uptake of beads by the microglia. Results are presented as fold induction over controls. Graphs 
represent results of n = 4 independent experiments. Differences between groups were tested using ANOVA 
followed by Tukey’s post hoc test. * = p < 0.05; ** = p < 0.01. (C) Anti-MAC3 stained sections of untreated 
control (CO), wild type (WT) and CXCL10-/- mice treated for one week with cuprizone. Note that MAC3 
immunoreactivity is similar in WT and CXCL10-/- animals. Scale bar 20 µm. 
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4.2 The growth factors FGF-2 and PDGFα are involved in oligodendrocyte maturation and 
homeostasis in vitro 
 
4.2.1 FGF-2 and PDGFα inhibit myelin gene expression in oligodendrocytes possibly via 
ERK signalling 
Oligodendrocyte precursor cells are a multipotent CNS precursor cell population and capable 
of myelin regeneration after a demyelinating event [175]. Remyelination, an important repair 
mechanism occurring in MS lesions, can restore axonal function and prevent axonal 
degeneration [176]. For correct remyelination it is necessary that balanced OPC proliferation 
and differentiation takes place. In MS patients remyelination is often incomplete at early 
disease stages and completely fails during chronic phase of the disease. The reason for 
remyelination failure in MS is still unknown [177]. However, a better understanding of 
oligodendrocyte biology will help to identify signalling mechanisms, which might be 
attractive targets for pro-remyelinating therapies in the future. Two important growths factors 
involved in OPC proliferation and differentiation are FGF-2 and PDGFα (reviewed in [178]). 
In my experiments FGF-2 and PDGFα-treated OPCs showed very little expression of typical 
myelin associated genes (i.e. Plp, Mag2, Mbp), indicative of a progenitor phenotype. I 
investigated in this part of the study if FGF-2 and PDGFα also influence the expression of 
myelin associated genes in mature oligodendrocytes and what pathways might be involved in 
FGF-2 and PDGFα signalling. To address the question if FGF-2 and PDGFα play a role in the 
regulation of myelin gene expression, I treated primary rat oligodendrocytes with basal 
oligodendrocyte medium containing either 10 ng/ml FGF-2 and/or 10 ng/ml PDGFα or 15 nM 
triiodo-L-thyronine (T3) and 10 ng/ml CNTF for 48 hours. As expected, stimulation with 
FGF-2 and/or PDGFα resulted in low expression levels of myelin genes (Mag2, Plp, Mbp) 
compared to basal medium control as shown in figure 13A-C. In contrast, cells treated with 
either T3/CNTF or vehicle (basal medium) showed significantly higher expression levels of 
myelin mRNA, indicative of a more mature cell phenotype. Note that control cells treated 
with basal oligodendrocyte medium show higher levels of myelin gene expression compared 
to GF-treated cells indicative of spontaneous differentiation occurring in the absence of FGF-
2 and PDGFα. This was confirmed for the myelin protein CNPase in the oligodendrocyte-like 
cell line OLN93, which showed low expression of CNPase protein after treatment with FGF-
2/PDGFα compared to high levels of CNPase protein after T3/CNTF or vehicle treatment 
(Fig. 13D). 
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Interestingly, mature oligodendrocytes that were first treated with T3 and CNTF showed 
reduced myelin mRNA expression after a following treatment with FGF-2 and PDGFα. This 
result indicates that FGF-2 and PDGFα suppress transcription of myelin genes in mature 
oligodendrocytes and thus result in a partial de-differentiation of the cells. 
In a next step I investigated which pathway might be involved in FGF-2 and PDGFα 
signalling. As seen in figure 13E, stimulation of rat OLN93 cells with FGF-2 and/or PDGFα 
lead to increased levels of phosphorylated ERK protein compared to unstimulated cells. Both 
proteins are described to activate ERK dependent pathways [179-181]. 
The down regulation of myelin genes is also a characteristic of the cuprizone model (compare 
Fig. 2G) Therefore, I investigated if cuprizone-treatment leads to an up regulation of the 
growth factors FGF-2 and PDGFα, which then might lead to down regulation of myelin 
genes. However, rtRT-PCR analysis of FGF-2 and PDGFα expression did not show 
differences between control and 2 days or 1 week cuprizone-treated mice (data not shown). 
Taken together, my results show that FGF-2 and PDGFα, beside their role in OPC 
proliferation, negatively influence maturation of oligodendrocytes in vitro. An imbalance in 
this growth factor system might thus account for some aspects of oligodendrocyte pathology 
observed in distinct MS lesion subtypes [182] and remyelination failure. 
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Figure 13 FGF-2 and PDGFα suppress myelin gene transcription in primary oligodendrocytes and activate 
ERK signalling in OLN93 cells. 
(A-C) rtRT-PCR of primary rat oligodendrocytes stimulated with basal oligodendrocyte medium alone (CO), or 
supplemented with 10 ng/ml FGF-2 and 10 ng/ml PDGFα (GF), 10 ng/ml FGF-2 or 10 ng/ml PDGFα alone, 
15nM T3 and 10 ng/ml CNTF (DIFF) or alternating with GF and DIFF for 48 hours. Note that the major myelin 
genes Mag2 (A), Plp (B) and Mbp (C) are down regulated by the growths factors FGF-2 and PDGFα, whereas 
more mature oligodendrocytes show increased myelin gene expression. Furthermore, GF inhibit the expression 
of myelin genes in mature oligodendrocytes. The graphs show results of n = 4 independent experiments. Values 
are given as arithmetic means ± SEM. Differences between groups were tested using ANOVA followed by 
Tukey’s post hoc test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (D) Western Blot analysis of CNPase 
expression by rat OLN93 cells after treatment with control medium (CO), 10 ng/ml FGF-2/PDGFα (GF) or 15 
nM T3/10 ng/ml CNTF (DIFF) for 48 hours. Note that treatment with GF leads to suppression of CNPase 
expression. Actin served as a loading control. (E) Western Blot analysis of phosphorylated ERK and total ERK 
expression in rat OLN93 cells after treatment of cells with basal oligodendrocyte medium alone (CO), or 
supplemented with 10 ng/ml FGF-2/PDGFα (GF), 10 ng/ml FGF-2 or 10 ng/ml PDGFα alone for 15, 30 and 60 
minutes. Total ERK protein served as a loading control. Note that growth factors strongly increase the amount of 
phosphorylated ERK after 15 min alone and in combination compared to vehicle control. Further note that ERK 
phosphorylation lasts longer in FGF-2 or FGF2/PDGFα co-treated cells compared with cells only treated with 
PDGFα. 
E 
phosphoERK 
 
total ERK 
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4.3 The chemokines CCL2 and CCL3 regulate cortical myelin integrity in the cuprizone 
model 
 
4.3.1 CCL2/3-/- mice are viable, fertile and show no gross physical or behavioural 
abnormality 
The chemokines CCL2 and CCL3 have been described to play important roles during MS 
disease course and cuprizone-induced demyelination [36, 117, 119]. I already showed that 
both chemokines, together with CXCL10 and CCL7 are up-regulated early during cuprizone-
treatment [183]. To study redundant functions of CCL2 and CCL3, I crossbred a new double 
knockout strain by mating the commercially available single knockout strains from Jackson 
laboratory. The F1 generation of heterozygous CCL2-/+/CCL3-/+ mice was further mated to 
obtain homozygous double knockout mice. Both genes are located on chromosome 11 with a 
distance of 1.24 cM meaning that the genes have a recombination frequency of 1.24 %. 
Homozygous CCL2/3-/- mice are viable, fertile and do not show any gross abnormalities under 
normal housing conditions. To identify double knockout mice, I performed a genotyping 
approach as illustrated in figure 14A. I chose a primer combination which detects a part of the 
wild type gene, or the transition site between the homologous wild type sequence and an 
initially introduced neomycin cassette [184-185]. In a semi-quantitative PCR, homozygous 
wild type mice displayed one band of 287 bp for the Ccl2 gene and one of 150 bp for the Ccl3 
gene, whereas knockout mice showed a 179 bp band for the disrupted Ccl2 and a 600 bp band 
for the disrupted Ccl3 gene (compare figure 14B). In contrast, heterozygous CCL2-/+ mice 
showed a 287 bp band for the Ccl2 wild type gene and a 179 bp band for the Ccl2 knockout 
gene as they posses both gene variants, one on each chromosome 11. This also applies for 
CCL3-/+ heterozygous mice, which showed two bands with 150 bp and 600 bp for the Ccl3 
wild type and Ccl3 knockout gene, respectively. 
To further verify the knockout on the DNA level, the PCR products of the knockout 
genotyping PCR were sequenced and compared to the wild type sequence of Ccl2 and Ccl3 as 
published at ENSEMBL (Ccl2: ENSMUSG00000035385 and Ccl3: 
ENSMUSG00000000982). Figure 14C shows a part of the sequencing result at the transition 
site of the neomycin cassette and the homologous recombination site of the mutant sequences 
paired with the wild type sequence of Ccl2 (upper sequence) or Ccl3 (lower sequence). I 
found that the sequenced DNA is partly homologous to the Ccl2 or Ccl3 gene representing the 
homologous recombination sites present in the vector, which was used to insert the disrupted 
sequence into the genome of the single knockout mice [184-185]. The adjacent non-
58 
 
homologous sequence did not give a specific result in a BLAST search and very likely 
represents a part of the neomycin cassette present in the disrupted gene (sequence of the 
neomycin cassette is not available). 
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Figure 14 Genotyping strategy and DNA sequencing of CCL2/3-/- mice 
(A) Genotyping strategy for wild type and CCL2/3 deficient (CCL2/3-/-) mice is presented. Note that the sense 
primer detecting the knockout is placed in the neomycin cassette which was inserted into the gene of interest 
when generating the original single knockout mouse. (B) Gel electrophoresis of semi-quantitative PCR 
genotyping of CCL2/3-/- mice and expected product size. (C) Breeding scheme and gene sequence obtained by 
sequencing the genotyping PCR products. Both genes are located on chromosome 11 with a distance of 1.24 cM 
(recombination frequency = 1.24%). Note that the mutant sequence is partially homologous to the wild type 
sequence representing the sites of homologous recombination during initial generation of the single knockout 
mice. The non-homologous part of the mutant sequence likely represents a part of the neomycin cassette and did 
not give a specific result in a BLAST mouse genome search. 
59 
 
4.3.2 CCL2 and CCL3 expression is disrupted in CCL2/3-/- mice 
In a next step, I verified in the mice the knockout of Ccl2 and Ccl3 on the mRNA and protein 
level. To study mRNA levels of Ccl2 and Ccl3 in double knockout mice, I fed wild type as 
well as CCL2/3-/- mice with 0.2% cuprizone for eight days. As shown in figure 15A, wild type 
mice display a strong expression of Ccl2 and Ccl3 transcripts after cuprizone-treatment 
compared to wild type control mice, whereas mRNA levels of Ccl2 and Ccl3 in CCL2/3-/- 
mice were almost not detectable. To examine protein levels of CCL2 and CCL3 in CCL2/3-/- 
mice, I performed ELISA experiments with primary astrocytes and peritoneal macrophages. 
Astrocytes and macrophages were treated with LPS as indicated in the figure legend and 
CCL2 and CCL3 protein levels were quantified in the cell culture supernatant. As shown in 
figures 15B and 15C both wild type cultures release significantly more CCL2 and CCL3 after 
LPS treatment compared to untreated wild type cells. This was not evident in cells obtained 
from CCL2/3-/- mice, confirming the absence of both proteins. Taken together, I could 
confirm that CCL2/3-/- mice do not express CCL2 and CCL3. 
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Figure 15 CCL2/3-/- mice do not express CCL2 and CCL3 protein 
(A) Expression of Ccl2 and Ccl3 mRNA in wild type (wt) and CCL2/3-/- mice after one week cuprizone-
treatment. Levels of Ccl2 and Ccl3 transcripts are strongly induced in wild type  mice after one week (1w) 
cuprizone-treatment compared to controls (Ccl2 co: 1± 0.25, 1w: 130 ± 31.3; Ccl3 co: 1 ± 0.15, 1w 50 ± 12.5), 
but not in CCL2/3-/- mice (Ccl2 co: 1.5 ± 0.5, 1w: 2.2 ± 0.7; Ccl3 co: 0.2 ± 0.05, 1w: 0.1 ± 0.04, n= 4 mice per 
group). Melting curve analysis revealed that CCL2/3-/- cDNA causes unspecific PCR products in the rtRT-PCR. 
(B) CCL2 and CCL3 protein levels in supernatant of control, 1 µg/ml and 10 µg/ml LPS stimulated wild type 
(Ccl2 co: 0.7 ± 0.1, 1 µg/ml: 12.3 ± 1.7, 10 µg/ml: 14.5 ± 1.4; Ccl3 co: not detectable = nd, 1 µg/ml: 1.1 ± 0.2, 
10 µg/ml: 1.8 ± 0.06) and CCL2/3-/- (Ccl2 co: 0.15 ± 0.1, 1 µg/ml: 1.1 ± 0.3, 10 µg/ml: 1.3 ± 0.07; Ccl3 co: nd, 
1 µg/ml: nd, 10 µg/ml: 0.013 ± 0.01) astrocytes. Note that protein levels of CCL2 and CCL3 are almost not 
detectable. (C) CCL2 and CCL3 protein levels in supernatant of control and 1 µg/ml LPS stimulated wild type 
(Ccl2 co: 0.2 ± 10-8, 1 µg/ml: 0.5 ± 0.032; Ccl3 co: nd, 1 µg/ml: 0.26 ± 0.05) and CCL2/3-/- (Ccl2 co: nd, 
1 µg/ml: nd; Ccl3 co: nd, 1 µg/ml: nd) peritoneal macrophages. No protein was detected in cells from CCL2/3-/- 
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mice. Male and female mice used. Values are given as arithmetic means ± SEM. Differences between groups 
were tested using ANOVA followed by Tukey’s post hoc test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
 
4.3.3 CCL2/3-/- mice display normal brain morphology 
To address the morphology and histology of the brain of CCL2/3-/- mice, coronary sections of 
6 week old male wild type and knockout mice were investigated using immunohistochemistry 
(Figs. 16A-D). Brains were sectioned from the levels 215-525 according to the mouse brain 
atlas of Sidman et al. (http://www.hms.harvard.edu/research/brain/atlas.html). Figure 16 
shows representative pictures of the level 305 from wild type and CCL2/3-/- mice. The main 
regions of interest were the medial corpus callosum (CC) and the layer 4 of the 
somatosensory cortex (Cx) as indicated in the heamtoxylin eosin stained overview. No gross 
abnormality was detected on the cellular level regarding GFAP+ astrocytes (Fig. 16A), IBA1+ 
microglia (Fig. 16B), OLIG2+ oligodendrocytes (Fig. 16C) or PLP+ myelin fibres (Fig. 16D). 
The number of astrocytes, microglia and oligodendrocytes was also statistically evaluated at 
all investigated brain levels and regions of interest (medial and lateral CC, Cx, gyrus dentatus 
and cerebellar white matter), but no significant differences were observed between wild type 
and CCL2/3-/- mice (data not shown). Furthermore, I investigated the morphology of the liver, 
spleen and kidney using haematoxylin eosin stain, but did not find any gross abnormalities 
(data not shown). Taken together, CCL2/3-/- mice show normal brain morphology and 
histology and no abnormalities in a basic investigation of three major organs. 
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Figure 16 CCL2/3-/- mice have normal brain morphology and histology 
Immunohistochemical and histochemical characterization of non-treated CCL2/3-/- mice compared to wild type 
controls. GFAP (A), IBA1(B), OLIG2 (C) and PLP (D) immunohistochemistry of CCL2/3-/- mice and wild type 
mice at the level 305 according to the mouse brain atlas of Sidman et. al. Regions of interest are indicated in the 
haematoxylin stained overview picture (rectangle indicates medial corpus callosum = CC, asterisk indicates layer 
4 of the somatosensory cortex = Cx). No gross abnormality was observed in CCL2/3-/- mice compared to wild 
type controls. Scale bar 50 µm.  
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4.3.4 CCL2/3-/- mice display less severe demyelination, astrogliosis and oligodendrocyte loss 
in the cortex after cuprizone-induced acute demyelination 
To address the role of CCL2 and CCL3 in cuprizone-induced demyelination, female mice 
were fed five weeks with 0.25 % cuprizone. Control animals received normal chow. This 
cuprizone-experiments were performed together with Cand. med. Mira Rickert. I found that 
CCL2/3-/- mice show significantly less severe demyelination (Fig. 17A) in the cortex 
compared to wild type mice which was paralleled by higher numbers of OLIG2+ 
oligodendrocytes (Fig. 17B) and less severe astrogliosis (Fig. 17C). No difference in the 
number of IBA1+ microglial cells was observed (Fig. 17D). In contrast, cellular and 
myelination parameters of the white mater tract corpus callosum were not different between 
wild type and CCL2/3-/- mice (Fig. 18A-D). These results suggest a region specific effect of 
chemokines in the cuprizone model. 
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Figure 17 Ccl2/3-/- mice show less severe demyelination after cuprizone- treatment in the cortex 
(A) Evaluation of anti-PLP staining intensity in wild type and CCL2/3-/- mice after 5 weeks cuprizone. CCL2/3-/- 
mice show considerably less demyelination in the cortex region after cuprizone-treatment compared to wild type 
(wt) mice (wt and CCL2/3-/- co: 100, wt 5w: 20.5 ± 5.3, CCL2/3-/- 5w: 70.5 ± 5.1). The right panel shows 
CCL -/- 
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representative pictures of anti-PLP stained sections of control (co) and five weeks (5w) cuprizone-treated wild 
type and CCL2/3-/- mice. Scale bar 100 µm (B) Analysis of anti-OLIG2 stained sections of control and 
cuprizone-treated wild type and CCL2/3-/- mice (left panel) and representative pictures of anti-OLIG2 stained 
sections of cuprizone-treated and control wild type and CCL2/3-/- mice (right panel). Note that CCL2/3-/- mice 
show more OLIG2+ cells in the cortex area compared to wild type mice after 5 weeks (5w) cuprizone-treatment 
(wt co: 269.9 ± 54.6 n = 3, CCL2/3-/- co: 346 ± 45.2 n = 4, wt 5w: 95.2 ± 14.7 n = 10, CCL2/3-/- 5w: 213.3 ± 19.4 
n = 9). (C) Evaluation of GFAP+ cells in the cortex of cuprizone-treated CCL2/3-/- and wild type mice and 
representative pictures of anti-GFAP immunohistochemistry. Note that CCL2/3-/- mice clearly have less GFAP+ 
astrocytes after five weeks (5w) cuprizone-treatment in the cortex compared to wild type mice (wt co: 29 ± 4.6,  
CCL2/3-/- co: 11.3 ± 2.4, wt 5w: 305 ± 30.5, CCL2/3-/- 5w: 195.8 ± 10.4). (D) Analysis of IBA1+ cells in the 
cortex of wild type and CCL2/3-/- mice treated five weeks with cuprizone and representative pictures of anti-
IBA1 immunohistochemistry. Cuprizone-treatment induces similar microgliosis in both wild type and CCL2/3-/- 
mice (wt co: 96.2 ± 22.9, CCL2/3-/- co: 114.4 ± 13.7, wt 5w: 254 ± 20.5, CCL2/3-/- 5w: 304 ± 14.2). Pictures of 
the cortex were taken at layer 4 of the primary somatosensory cortex. Scale bar (B-D) 50 µm. Values are given 
as arithmetic means ± SEM. Differences between groups were tested using ANOVA followed by Tukey’s post 
hoc test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
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Figure 18 No difference between Ccl2/3-/- mice and wild type mice was observed in the corpus callosum after 5 
weeks cuprizone-treatment 
(A) Evaluation of anti-PLP staining intensity in wild type and CCL2/3-/- mice after 5 weeks (5w) cuprizone-
treatment in the corpus callosum. Scale bar 100 µm. CCL2/3-/- and wild type mice show a similar degree of 
demyelination (wt and CCL2/3-/- co: 100, wt 5w: 10.6 ± 4.5, CCL2/3-/- 5w: 12.4 ± 3.2). The right panel shows 
representative pictures of anti-PLP stained sections of control and five weeks cuprizone-treated wild type and 
CCL2/3-/- mice at the midline of the corpus callosum. (B) Analysis of anti-OLIG2 stained sections of control and 
cuprizone-treated wild type and CCL2/3-/- mice (left panel) and representative pictures of anti-OLIG2 stained 
CCL2/3-/- 
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sections of cuprizone-treated and control wild type and CCL2/3-/- mice (right panel) in the midline of the corpus 
callosum (wt co: 1158 ± 231 n = 3, CCL2/3-/- co: 1398 ± 189.4 n= 4, wt 5w: 1238 ± 148.8 n= 10, CCL2/3-/- 5w: 
1185 ± 113.5 n = 9). Scale bar 50 µm (C) Evaluation of GFAP staining intensity in the corpus callosum of 
control and cuprizone-treated CCL2/3-/- and wild type mice and representative pictures of anti-GFAP 
immunohistochemistry in the midline of the corpus callosum (wt co: 1 ± 0.07,  CCL2/3-/- co: 1.02 ± 0.008, wt 
5w: 1.68 ± 0.14, CCL2/3-/- 5w: 1.6 ± 0.1). (D) Analysis of IBA1 staining intensity in the midline of the corpus 
callosum of wild type and CCL2/3-/- mice treated five weeks with cuprizone and representative pictures of anti-
IBA1 immunohistochemistry. Cuprizone-treatment induces similar microgliosis in both wild type and CCL2/3-/- 
mice (wt co: 1 ± 0.01, CCL2/3-/- co: 1.008 ± 0.02, wt 5w: 1.87 ± 0.08, CCL2/3-/- 5w: 2.1 ± 0.1). Intensity of 
GFAP and IBA1 staining was evaluated using ImageJ software as described in materials and methods. Scale bar 
100 µm. Values are given as arithmetic means ± SEM. Differences between groups were tested using ANOVA 
followed by Tukey’s post hoc test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
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5. Discussion 
 
5.1 Oligodendrocyte-derived chemokine CXCL10 triggers microglial activation in the 
cuprizone model 
In the first part of this thesis I showed that the chemokine CXCL10 is critically involved in 
early cuprizone-induced microglia activation as demonstrated by lower numbers of IBA1-
expressing cells in CXCL10-deficient animals. As I found Cxcl10 mRNA expressed in 
interfascicular cells indicative for mature, myelinating oligodendrocytes (compare figure 6), 
these results suggest that oligodendrocytes are involved in early microglia activation. The 
assumption that oligodendrocytes express and secrete chemotactic molecules under 
pathological conditions is highlighted by my finding that cultured oligodendrocytes, exposed 
to IFNγ, up-regulate CXCL10 expression and release and are able to contribute to an 
inflammatory environment by activating microglial cells in a CXCL10-depending manner. 
CXCL10 expression is classically regulated by IFNγ signalling [186] and was already shown 
to be present in IFNγ-treated oligodendrocyte cultures by Balabanov and colleagues [187]. 
Although several efforts were done to visualize CXCL10 protein by using specific antibodies 
on sections of cuprizone-treated mice, these results were not reliable since signal intensities 
were comparable in wild type as well as CXCL10-deficient mice (data not shown). Therefore, 
the active contribution of oligodendrocytes in microglia activation has to be critically 
evaluated in future studies using for instance double-labeling ISH-techniques to prove the co-
localization of Cxcl10 mRNA and oligodendrocyte-specific mRNA. However, these results 
provide first evidence that oligodendrocytes are involved in inflammatory signalling in the 
CNS. The contribution of oligodendrogliopathy to MS pathology as a preceding phenomenon 
before immune cell invasion is controversially discussed in the literature (reviewed in [6, 
188]). A number of experimental studies have demonstrated a strong positive correlation 
between oligodendrocyte susceptibility to injury and the extent of CNS inflammation in 
experimental MS models. In mice double heterozygous for the LIFR-null mutation and a 
gp130 intracellular truncation, absence of LIF signalling increased oligodendrocyte 
susceptibility to injury and augmented the inflammatory reaction and the severity of 
symptoms [70]. In addition, mice lacking pro-apoptotic genes or over-expressing anti-
apoptotic molecules, exclusively in oligodendrocytes, display resistance to EAE and 
inflammatory demyelination [71-72]. The critical role of oligodendrocytes in CNS 
inflammation is further exemplified in mice with peroxisome-deficient oligodendrocytes 
which develop spontaneous neuroinflammation [189]. The molecular mechanisms linking 
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oligodendrocyte stress with the regulation of early microgliosis remain poorly understood. 
However, the results from my work support the findings of these studies that 
oligodendrocytes regulate neuroinflammatory processes. 
In this study CXCL10 is a critical regulator of early microglia activation after cuprizone-
treatment. Interestingly, Tirotta and colleagues found that CXCL10 had a detrimental effect 
on oligodendrocyte cultures treated with IFNγ [172]. One might speculate that CXCL10-
deficient mice thus display less cuprizone-induced oligodendrocyte apoptosis leading to less 
microglia activation, which I could not confirm in this study. The differences in the in vitro 
experiments, where I also did not find increased oligodendrocyte apoptosis in the presence of 
CXCL10, are possibly due to the shorter treatment period used in my protocols or lower 
levels of CXCL10 compared to the concentrations used in the study of Tirotta and colleagues. 
Furthermore, I did not find an upregulation of IFNγ in the genome-wide array analysis of 
cuprizone-exposed animals, suggesting that the early expression of CXCL10 by 
oligodendrocytes is an IFNγ-independent mechanism in the cuprizone model. This might be 
different at later time points of cuprizone-induced demyelination where IFNγ expression has 
been described [190]. Nevertheless, activation of microglial cells by oligodendrocyte-derived 
CXCL10 might result in the expression of IFNγ or other inflammatory cytokines by microglia 
or astrocytes, contributing to an inflammatory environment and demyelination. In addition, 
CXCL10 has been described to directly affect the recruitment of peripheral immune cells into 
the subventricular zone of EAE mice, thus being able to directly increase neuroinflammation 
[191]. In MS, IFNγ plays a critical role in disease pathogenesis. It is predominantly expressed 
by activated, self-reactive CD4+ and natural killer cells, and positively correlates with disease 
activity in EAE [192]. Furthermore, IFNγ expression increases in the two weeks preceding 
attacks of MS [193] suggesting that this cytokine is involved in the development of new MS 
lesions. I speculate that oligodendrocytes initially activate microglial cells and thus contribute 
directly or indirectly to T-cell infiltration. In turn, invading T-cells might activate 
oligodendrocyte-derived chemokine/cytokine release (e.g via IFNγ-signalling) inducing a pro-
inflammatory “circulus vitiosus”. Finally this would lead to an active, demyelinating brain 
focus and consequently disease progression. 
Results of previous studies suggest that CXCL10 is involved in the pathogenesis of MS [194-
195]. Our knowledge which cells express CXCL10 under demyelinating conditions is 
immature. In one study, CXCL10 was found to be expressed by endothelial cells [196] 
whereas in another study, CXCL10 staining associated with astrocytic processes [197]. 
Except for the fact that CXCL10 is expressed after cuprizone-treatment [198] not much is 
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known about the cellular source and function of CXCL10 during cuprizone-induced 
oligodendrogliopathy. Although I found CXCL10 expression in oligodendrocytes, other cells 
possibly contribute to CXCL10 accumulation during early cuprizone-induced 
oligodendrogliopathy. For instance, Skripuletz and colleagues recently showed that CXCL10 
is predominantly expressed by astrocytes after a five weeks cuprizone exposure when 
inflammation and demyelination is on its peak [199]. Here, it is important to point out that in 
the present study mice were analyzed very early after oligodendrocyte injury before 
significant demyelination can be detected and overt astrocyte activation is evident [34, 36]. I 
speculate that CXCL10 plays a role during early and late stages of lesion development, with a 
change in the CXCL10-expressing cell population. Nevertheless, I cannot formally rule out 
that astrocytes participate in early microglia activation in this model. A greater number of 
studies are aiming to define the role of CXCL10 in the inflammatory demyelination model 
EAE than in the cuprizone model, but these studies have produced conflicting results. 
Predicting on one hand positive properties of CXCL10 [125] and on the other hand negative 
properties [124], for example oligonucleotide-blocking of Cxcl10 transcript reduced clinical 
signs in MBP-induced EAE [200], whereas CXCL10 knockout animals show more severe 
EAE [126]. The relevance of these and my study for MS lesion development has to be 
addressed in the future. 
In summary, my results strongly suggest that stressed oligodendrocytes release CXCL10, 
which activates microglia suggesting that oligodendrocytes can actively participate in the 
initiation of neuroinflammatory events. 
 
5.2 The growth factors FGF-2 and PDGFα are involved in oligodendrocyte maturation and 
homeostasis in vitro 
The importance of FGF-2 and PDGFα on OPC proliferation and differentiation has been 
extensively discussed in the literature [201-204] and both molecules or members of their 
downstream signalling pathways, respectively, are discussed as possible targets for the 
treatment of remyelination and remyelination failure in MS [177, 205-206]. In this part of the 
study I could confirm that FGF-2 and PDGFα significantly suppress the expression of major 
myelin genes (i.e. Mag2, Plp, Mbp and Cnp) in OPCs, thus maintaining the precursor status of 
the cells. Interestingly, the growth factors also suppress myelin gene expression in already 
mature, myelin gene expressing oligodendrocytes in vitro, leading to a de-differentiated 
phenotype of the cells with probably impaired myelination capacity. This is in line with 
findings from Fressinaud and colleagues [207]. In the CNS astrocytes are a major source of 
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FGF-2 and PDGFα [203, 208]. Since MS lesions show high numbers of activated astrocytes 
high levels of FGF-2 and PDGFα expression can be expected. Indeed, high levels of FGF-2 
have been found in the CSF of MS patients correlating with relapses [209]. Furthermore 
numbers of PDGFαR-expressing oligodendrocytes are elevated in MS lesions, also indicating 
a role for PDGFα-dependent OPC proliferation in MS [210]. In principal the process of 
remyelination taking place in demyelinated brain tissue includes three steps: First, OPCs will 
proliferate and migrate to the demyelinated lesion; second, differentiate to mature 
oligodendrocytes; and third, get in contact with demyelinated axons to start the remyelination 
process [211-212]. This process involves not only FGF-2 and PDGFα, but also a broad 
variety of cytokines, chemokines, hormones and other growth factors [51, 213]. However, if 
an imbalance exists between proliferative and maturing signals for instance in the presence of 
very high numbers of activated astrocytes, the differentiation of OPCs and thus remyelination 
fails and even mature oligodendrocytes might suffer from the de-differentiating stimulus they 
encounter. Interestingly, remyelination failure in chronic MS lesions is likely not due to a lack 
of OPCs, as there generally are sufficient numbers of OPCs for successful remyelination in 
the lesion area [210], but the maturation of these OPCs seems to be impaired especially at 
later chronic disease stages [78]. Beside growth factors also other mechanism have been 
described that might account for disturbed remyelination in chronic MS lesions, among them 
expression of remyelination inhibiting factors, decreasing susceptibility of axons for 
remyelination, formation of the glial scar and aging of OPCs [177, 206, 214]. 
At first glance increasing proliferation of OPCs via FGF-2/PDGFα signalling in demyelinated 
tissues seems to be a favourable idea to support the remyelination process. However, my 
results indicate that growth factors play ambivalent roles in the remyelination process, which 
has also been shown in different animal models of MS (reviewed in [215]). A fact that has to 
be considered when investigating new disease modifying treatments, addressing OPC 
proliferation and maturation to promote remyelination in MS patients. 
 
5.3 The chemokines CCL2 and CCL3 regulate cortical myelin integrity in the cuprizone 
model 
CCL2 (MCP1) and CCL3 (MIP1α) are among the best characterized chemokines and have 
been described in MS pathology as well as in its various animal models [123, 216]. During 
this study, analysis of chemokine gene expression levels revealed that Ccl2 and Ccl3 mRNA 
are up-regulated early after cuprizone-treatment (compare figure 4). Nevertheless, when 
investigating the role of CCL2 and CCL3 in early cuprizone-induced microglia activation no 
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significant differences were found compared to wild type mice. Due to their highly conserved 
structure many chemokines display redundant functions as they bind to the same receptor 
[91]. Therefore, we decided to generate a double knockout strain of these two distinct 
chemokines. By extensive cross-breeding of the commercially available single knockout 
strains I was able to generate a new strain that does not show expression of CCL2 or CCL3 
protein. Since the mice are viable, fertile and do not display any gross abnormality or 
pathology, they provide an interesting tool to study redundant functions of CCL2 and CCL3 
not only in the context of MS, but also in other disease conditions linked to inflammation 
and/or cell migration. 
When conducting a first five week cuprizone trial I found interesting differences between 
CCL2/3-/- mice compared to wild type mice in the cortex (Cx) but not in the corpus callosum 
(CC). The demyelination of the Cx of cuprizone-treated C57BL/6 mice has already been 
described [217]. Interestingly, CCL2/3-/- mice showed less demyelination together with higher 
numbers of OLIG2+ oligodendrocytes indicating a role of these chemokines, either directly or 
indirectly, in acute cuprizone-induced demyelination. Whether the higher number of 
oligodendrocytes is due to less oligodendrocyte apoptosis or increased proliferation of OPCs 
is still an open question. Furthermore, it was not investigated if the mice truly display less 
demyelination or if they show simultaneously increased remyelination. One might speculate 
that less demyelination in these mice is caused by less inflammation in the Cx area, but I did 
not find significantly less microglia activation in CCL2/3-/- mice compared to wild type mice, 
indicating similar levels of inflammation. However, astrocyte activation was less severe in 
CCL2/3-/- mice indicating a role for astrocyte-mediated pathways in demyelination and 
oligodendrocyte survival/proliferation. Since astrocytes are described to secrete growth 
factors important for oligodendrocyte proliferation [203, 208] ), less astrocyte activation 
might lead to increased oligodendrocyte maturation and thus remyelination. When 
demyelination and remyelination processes take place at the same time, histopathological 
investigation might lead to the impression that less demyelination is occurring in the mice. To 
answer this question other methods like electron microscopy have to be used to distinguish 
between normally myelinated and remyelinated axons. Ongoing studies will address the 
question if one of the two chemokines or both together account for the described changes. 
It is remarkable that the deletion of two chemokines has such a strong region-specific effect in 
cuprizone-treated mice. One major difference between the CC and the Cx is the content of 
myelin. That myelin debris is at least partially responsible for the differences in inflammatory 
white and gray matter demyelination has already been described in MS and in the cuprizone 
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model by our group [218]. Here, I speculate that the enormous amount of myelin debris in the 
CC covers the effects of CCL2 and CCL3 deficiency as inflammation is tremendously high. 
The myelin-poor Cx, showing a priori less inflammation [36, 217] is thus more receptive for 
changes in the molecular composition. In MS, the pathology of gray matter lesions is believed 
to differ from white matter lesions in several aspects, such as less pronounced lymphocyte 
infiltration, macrophage activity, complement composition, or blood-brain-barrier (BBB) 
alterations [219-222]. The observed differences could be due to differences in the 
composition and function of the BBB or other elements of the cytoarchitecture of the cerebral 
Cx, that makes it more resistant to inflammation [219]. Taking together these results 
demonstrate that white and gray matter regions differ in their response to pathological 
challenges of the cuprizone-treatment. With respect to MS pathology, future studies have to 
take into consideration that white and gray matter display different regions not only in their 
cytoarchitecture, but also in terms of their molecular composition. 
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6. Work contribution 
 
6.1 External collaboration partners 
Prof. Luc Valliéres (Department of Neurosciences, Laval University Hospital Research 
Center, Quebec G1V 4G2, QC, Canada) performed radioisotopic labelled in situ 
hybridization. 
Prof. Harald Neumann, Dr. Clara Beutner and Dr. Bettina Linnartz-Gerlach (Neural 
Regeneration Group, Institute of Reconstructive Neurobiology, University of Bonn, 53127 
Bonn, Germany) performed rtRT-PCR and migration assays on mouse embryonic stem cell 
derived microglial cells. 
 
6.2 Collaboration partners at RWTH Aachen University 
Prof. Werner Baumgartner (Department of Cellular Neurobionic, Institute for Biology II 
RWTH Aachen, 52056 Aachen, Germany) performed the electron microscopy experiments in 
cuprizone-treated mice. 
Dr. Bernd Denecke (Interdisciplinary Centre for Clinical Research (IZKF) Aachen, RWTH 
Aachen University, 52074 Aachen, Germany) performed microarray analysis of tissue from 
cuprizone-treated mice. 
 
6.3 Contribution of colleagues from the Institute of Neuroanatomy, RWTH Aachen University 
M.Sc. Tobias Reiß was involved in the basic immunohistochemical characterization of 
CCL2/3-/- mice. 
Cand. med. Mira Rickert was involved in the conduction and immunohistochemical 
evaluation of the 5 weeks cuprizone experiment with CCL2/3-/- wild type mice.  
MD Barbara Krauspe was involved in the cuprizone experiments used for microarray analysis 
and together with Dr. Jan-Phillip Buschmann performed the immunohistochemical and 
molecular characterization of short-term cuprizone-treated mice (wild type mice treated for 2 
days and 1 week). 
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8. Summary 
Multiple sclerosis (MS) is a demyelinating disorder of the central nervous system classically 
discussed as an autoimmune disease. However, recent neuropathological evidence suggests 
that primary oligodendrogliopathy might trigger the inflammatory response during MS lesion 
development. In my thesis I showed that cuprizone-treatment induced a distal 
oligodendrogliopathy within days that was paralleled by early microgliosis. The chemokines 
CXCL10, CCL2 and CCL3 were found to be upregulated in this tissue. In CXCL10, but not 
CCL2 and CCL3 deficient mice, microglia recruitment was decreased indicating a pivotal role 
of CXCL10 in the initiation of inflammatory foci. CXCL10 was found to be predominantly 
expressed by damaged oligodendrocytes. Further in vitro studies confirmed that 
oligodendrocyte-derived CXCL10 induced microglia migration and a pro-inflammatory M1-
phenotype. In summary, my results show that stressed oligodendrocytes release CXCL10, 
which activates microglia suggesting that oligodendrocytes can actively participate in the 
initiation of neuroinflammatory events. 
In the second part of my thesis I investigated the role of the growth factors FGF-2 and PDGFα 
on oligodendrocyte precursor cell (OPC) maturation, a process necessary to achieve correct 
and sufficient remyelination in MS lesions. FGF-2 and PDGFα treatment of primary OPCs 
showed that both growth factors negatively influence maturation of oligodendrocytes in vitro. 
An imbalance in this growth factor system might thus account for some aspects of 
oligodendrocyte pathology observed in distinct MS lesion subtypes and remyelination failure. 
In the last part of my thesis I investigated redundant functions of the chemokines CCL2 and 
CCL3 using a newly bred double knockout mouse strain (CCL2/3-/-) deficient in both genes. 
A basic investigation of the mice confirmed the absence of CCL2 and CCL3 on the mRNA 
and protein level and revealed that the mice show no gross abnormalities in brain tissue 
morphology and histology. Interestingly, a 5 weeks cuprizone-trial showed that CCL2/3-/- 
mice display regional differences with less severe demyelination, oligodendrocyte loss and 
astroglia activation in the cortex, but not in the corpus callosum compared to wild type mice. 
With respect to MS pathology, future studies have to take into consideration that white and 
gray matter display different regions with respect to their cytoarchitecture and molecular 
composition. 
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Zusammenfassung 
Die multiple Sklerose (MS) ist eine demyelinisierende Erkrankung des zentralen 
Nervensystems, die klassischerweise als Autoimmunerkrankung angesehen wird. Eine Reihe 
neuropathologischer Studien deuten jedoch drauf hin, dass eine primäre 
Oligodendrogliopathie ein Trigger der Immunantwort während der MS Läsionsentstehung ist. 
In meiner Arbeit konnte ich zeigen, dass die Behandlung mit Cuprizone in kurzer Zeit zu 
einer distalen Oligodendrogliopathie führt, die mit einer frühen Mikrogliose einhergeht. Dabei 
sind die Chemokine CXCL10, CCL2 und CCL3 im Gewebe hochreguliert. Weitere 
Untersuchungen mit CXCL10, CCL2 und CCL3 defizienten Mäusen zeigten, dass 
ausschließlich CXCL10 defiziente Mäuse eine verringerte Mikroglia-Rekrutierung nach 
Cuprizone-Gabe zeigen. Dies verdeutlicht die wichtige Rolle von CXCL10 für die frühe 
Immunantwort. Es konnte zudem gezeigt werden, dass CXCL10 hauptsächlich von 
geschädigten Oligodrozyten exprimiert wird. Weiterführende in vitro Versuche bestätigten, 
dass von Oligodendrozyten produziertes CXCL10 die Migration von Mikrogliazellen 
stimuliert und zur Aktivierung eines pro-inflammatorischen M1-Phänotyps in den 
Mikrogliazellen führt. Meine Ergebnisse zeigen, dass gestresste Oligodendrozyten CXCL10 
produzieren, welches wiederum Mikrogliazellen aktiviert und somit Oligodendrozyten eine 
aktive Rolle in der Initiierung neuroinflammatorischer Prozesse übernehmen können. 
Im zweiten Teil meiner Arbeit habe ich den Effekt der Wachstumsfaktoren FGF-2 und 
PDGFα auf die Ausreifung von Oligodendrozytenvorläufern (OPC) untersucht, ein Prozess 
der notwendig ist eine korrekte und ausreichende Remyelinisierung in MS Läsionen zu 
erreichen. Die in vitro Behandlung von primären OPCs mit FGF-2 und PDGFα zeigte, dass 
beide Wachstumsfaktoren die Ausreifung der Zellen negativ beeinflussen. Eine Störung 
dieses Wachstumsfaktor-Systems könnte für einige Aspekte der Oligodendrozytenpathologie 
bestimmter MS Läsionen verantwortlich sein und eine Rolle beim Versagen der 
Remyelinisierung spielen. 
Im letzten Teil meiner Thesis untersuchte ich redundante Funktionen der Chemokine CCL2 
und CCL3 mittels einer neu gezüchteten “knockout” Mauslinie (CCL2/3-/-) der beide 
Chemokine fehlen. Eine Grundcharakterisierung der Mäuse ergab, dass die Tiere keine CCL2 
oder CCL3 mRNA bzw. Proteine produzieren und dass die Mäuse keine besonderen 
Veränderungen der Hirnmorphologie oder Histologie aufweisen. Interessanterweise zeigte 
sich nach einem 5 Wochen Cuprizone-Versuch, dass die CCL2/3-/- Mäuse im Vergleich zu 
Wildtyp Mäusen regionale Unterschiede in der Histopathologie des Cortex, jedoch nicht des 
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Corpus callosum aufweisen. Dazu zählen eine verringerte Demyelinisierung, weniger 
Oligodendrozytenapoptose und eine verringerte Astrogliose. Zukünftige Studien, die sich mit 
der MS Pathologie befassen, sollten demnach die zellulären und molekularen Unterschiede 
der weißen und grauen Substanz stärker berücksichtigen.  
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